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Abstract
Endometrial cancer is the most common gynecologic cancer in the United States with
recent trends showing a continued increase in incidence and mortality. Prognosis is
influenced by cancer stage at diagnosis and differs by race/ethnicity. Researchers have
documented poorer survival among Blacks than Whites diagnosed with endometrial
cancer. The 5-year survival rates for women with endometrial cancer is 81%; while
survival for White and Black women are 84% and 62%, respectively. There is a gap in
literature examining the widening disparity in incidence and survival of women
diagnosed with advanced stage disease among population subgroups across the United
States. The purpose of this study was to ascertain the factors associated with endometrial
cancer survival disparities in the United States. The social ecological model was utilized
as a conceptual framework to guide this study. Using epidemiologic data obtained from
the National Cancer Institute’s Surveillance, Epidemiology, and End Results [SEER]
database, the cross-sectional study included 115,997 women diagnosed with endometrial
cancer between 2007 and 2016. Variables associated with the outcomes of interest were
assessed using multilevel logistic regression and multilevel Cox-proportional hazards
models. Multivariable analyses showed that race/ethnicity, increased age, aggressive
histology, poor tumor grade, and advanced-stage disease were associated with increased
risk of endometrial cancer mortality. This research provides insights into the contributing
factors associated with disparities in endometrial cancer survival and can lead to positive
social change by developing health programs and policies that improve the survival
outcomes of women who have been diagnosed with late-stage endometrial cancer.
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Section 1: Foundation of the Study and Literature Review
Introduction
Endometrial cancer survival disparities represent a significant public health
problem in the United States despite several efforts at the local and national level to
tackle inequalities in health care (O’Keefe et al., 2015). The number of women diagnosed
with endometrial cancer has increased over the last decade, and incidence rates are
projected to continue to rise (Sheikh et al., 2014). Based on National Cancer Institute
(NCI) 2010–2016 cancer statistics, endometrial cancer accounts for 3.6% of all new
cancer cases in the United States (NCI SEER, 2020). According to the Centers for
Disease Control and Prevention (CDC), deaths from endometrial cancer increased by 2%
each year for White and Black women from 2007 to 2014 (CDC, 2014). With prognosis
strongly related to stage at diagnosis, the 5-year survival rate for all endometrial cancer
cases is about 81.0% (NCI SEER, 2020).
Compared with Caucasians, African Americans in the United States are more
likely to experience worse health outcomes across a range of diseases including obesity,
cardiovascular diseases, diabetes, and other malignancies (Farley et al., 2007; Onstad et
al., 2016; Randall & Armstrong, 2003; Ruterbusch et al., 2014). The same holds true for
gynecologic cancers; several studies have documented that African American women
report higher rates of morbidity and mortality for endometrial, ovarian and cervical
cancers (Chatterjee et al., 2016; Collins et al., 2014; Rauh-Hain et al., 2018). Endometrial
cancer exhibits particularly striking racial differences. Research shows a 30% decrease in
incidence among African American patients diagnosed with endometrial cancer;
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however, they are 2.5 times more likely than Whites to die from the disease (Jemal et al.,
2010). Although histology and socioeconomics are the most consistent contributors to
endometrial cancer incidence and mortality (Long et al., 2013), the cause of these
disparities is multifaceted.
Despite a vast pool of literature describing disparities in endometrial cancer, the
causes of these inequalities are not well understood; factors such as patient and disease
characteristics, inconsistencies in treatment and socioeconomic differences may
contribute significantly to observed disparities (Kish et al., 2014; Rauh-Hain et al., 2015;
Setiawan et al., 2015). Hence, understanding the interplay of each of these factors can
contribute to effective healthcare policy recommendations that could narrow the survival
disparity gap significantly thus resulting in potential positive social change implications
for this study. The findings from this study will provide insights into determinants of
endometrial cancer racial/ethnic disparities, inform policy-makers about subpopulations
that are disproportionately affected by the disease, and update knowledge on the trend of
endometrial cancer racial/ethnic disparities based on a national level cancer registry data.
This section includes the problem, purpose, and nature of this study. The section
also includes the research questions and hypotheses, the theoretical framework on which
the study is based, as well a comprehensive review of literature. I will also discuss the
study assumptions, limitations, and significance. I discuss the potential implications for
positive social change in relation to understanding that factors associated with survival
disparities are a potential public health component for developing interventions targeted
toward lessening the burden of endometrial cancer.
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Problem Statement
According to the National Cancer Institute (NCI), endometrial cancer accounts for
95% of cancer of the uterine corpus cases (NCI, 2018). The American Cancer Society
(ACS) describes endometrial cancer as cancer of the endometrium i.e. the lining of the
uterus. It occurs when cells of the endometrium grow too quickly and may thicken at
certain areas to form a mass of tissue called a tumor (ACS, 2018). The cancer statistic
review published by Cronin et al. (2018) based on data from the NCI’s Surveillance
Epidemiology and Ends Results Program (SEER) described endometrial cancer,
sometimes called uterine cancer, as the fourth most commonly diagnosed cancer and the
seventh leading cause of cancer-related deaths among U.S. women. In 2013, an estimated
50,560 women were diagnosed, and 9,325 women died from uterine cancer in the United
States (Siege et al., 2013). According to the American Cancer Society (2018), it is
estimated that 61,880 women in the United States will be diagnosed with endometrial
cancer and 12,160 will die from the disease in 2019.
Endometrial cancer health disparities include differences in incidence, prevalence,
mortality, and survival particularly among marginalized segments of the population
(DeSantis et al., 2016). Several researchers have suggested that racial differences exist in
the incidence and mortality of endometrial cancer (DeSantis et al., 2016; Smotkin et al.,
2012). According to the Centers for Disease Control and Prevention (CDC), the incidence
rate for malignant tumors of the uterine corpus is 30% lower in African-American
women compared to White women (CDC, 2013); however, the mortality rate is much
higher at 85% for African American women.
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Epidemiological evidence as documented in numerous studies has shown that
survival disparity in Black women is thought to be multifactorial including the potential
influence of race/ethnicity, socioeconomic status, histologic subtypes, and treatment
factors on disease-specific mortality (Cote et al., 2015; Kost et al., 2019; Long et al.,
2013; Rauh-Hain et al., 2015). However, it remains unclear why racial differences in
survival persist after accounting for these factors. Disparities in endometrial cancer
diagnosis, treatment, and survival outcome using current national-level cancer registry
data have not been thoroughly examined. It remains unclear whether racial/ethnic
disparities in endometrial cancer outcomes have changed over the last decade. There is a
gap in literature examining the widening disparity in incidence and survival for
increasing rates of aggressive tumor subtypes among African American women. In a
cancer statistics report by Chatterjee et al. (2016), African American women are more
likely than White women to be diagnosed with late-stage cancer, high-grade tumors
(Grade III or Grade IV), and poorer prognosis due to histological subtypes. Additionally,
Tarney et al. (2018) found that Black women with endometrial cancer suffer significantly
worse outcomes regardless of age, stage, and grade of disease.
Furthermore, there is also a gap in knowledge surrounding the role of
access to care and its association with racial differences in uterine cancer survival. Hence,
the need to examine socioeconomic factors, specifically the impact of insurance status
and stage of diagnosis on endometrial cancer survival. For several cancer types including
uterine cancer, uninsured and Medicaid insured patients experience higher mortality and
lower survival outcomes than patients with private insurance (Fedewa et al., 2011; Niu et
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al., 2013; Sohn, 2017). There are limited studies on the differential effects of insurance
status on endometrial cancer outcomes. Even fewer uterine cancer survival studies have
been carried out using population-based datasets such as SEER to examine differences in
survival of women diagnosed with endometrial cancer (Fedewa et al., 2011; Niu et al,
2013). This might be due to the fact that insurance information was not released on the
SEER database until 2012 when data were first published for cancer cases diagnosed
from 2007 upwards (NCI SEER, 2013). Hence, exploring the determinants that contribute
to endometrial cancer survival disparities is an important public health approach toward
reducing the burden of disease.
Purpose of the Study
The purpose of this study was to conduct a retrospective, cross-sectional,
quantitative analysis to ascertain the determinants of endometrial cancer survival
disparities in the United States over the past decade. The main outcome variables
(dependent variables) were endometrial cancer stage at diagnosis, treatment, and survival.
The key independent variables for this study were insurance coverage, and three other
factors that have been shown to be associated with disparities in endometrial cancer
mortality: race/ethnicity, histologic subtype, and tumor grade. The covariables included
in study analysis were women’s age at diagnosis and marital status.
Research Questions and Hypotheses
In this study I addressed the following questions and hypotheses:
Research Question 1 (RQ1): Are race/ethnicity, age at diagnosis, histologic
subtype, tumor grade, insurance, stage at diagnosis, and marital status associated with
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late-stage diagnosis of endometrial cancer (Stage III and IV) in the United States as
compared to women with Stage I and II endometrial cancer diagnosis?
Null Hypothesis (H01): The determinants: race/ethnicity, age at diagnosis,
histologic subtype, tumor grade, insurance, stage at diagnosis, and marital status are not
associated with late-stage endometrial cancer diagnosis (Stage III and IV) in the United
States as compared to women with Stage I and II endometrial cancer diagnosis.
Alternative Hypothesis (Ha1): The determinants: race/ethnicity, age at diagnosis,
histologic subtype, tumor grade, insurance, stage at diagnosis, and marital status are
associated with late-stage endometrial cancer diagnosis (Stage III and IV) in the United
States as compared to women with Stage I and II endometrial cancer diagnosis.
Research Question 2 (RQ2): Are race/ethnicity, age at diagnosis, histologic,
subtype, tumor grade, insurance, stage at diagnosis, and marital status associated with
receipt of surgery in women diagnosed with endometrial cancer in the United States?
Null Hypothesis (H02): The determinants: race/ethnicity, age at diagnosis,
histologic subtype, tumor grade, insurance, stage at diagnosis, and marital status are not
associated with receipt of surgery in women diagnosed with endometrial cancer in the
United States.
Alternative Hypothesis (Ha2): The determinants: race/ethnicity, age at diagnosis,
histologic subtype, tumor grade, insurance, stage at diagnosis, and marital status are
associated with receipt of surgery in women diagnosed with endometrial cancer in the
United States.
Research Question 3 (RQ3): Are there racial/ethnic differences in 5-year survival
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of women diagnosed with endometrial cancer in the United States?
Null Hypothesis (H03): There is no significant difference by racial/ethnicity in 5year survival of women diagnosed with endometrial cancer in the United States.
Alternative Hypothesis (Ha3): There is a significant difference by racial/ethnicity
in 5-year survival of women diagnosed endometrial cancer in the United States.
Research Question 4 (RQ4): Is there a significant difference in 5-year survival by
health insurance status of women diagnosed with endometrial cancer in the United
States?
Null Hypothesis (H04): There is no significant difference in 5-year survival by
health insurance status of women diagnosed with endometrial cancer in the United States.
Alternative Hypothesis (Ha4): There is a significant difference in 5-year survival
by health insurance status of women diagnosed with endometrial cancer in the United
States.
I conducted the quantitative data analysis to examine the relationship between the
independent and dependent variables while controlling for confounding factors. I will
discuss the results in Section 3 in detail.
Theoretical Foundation for the Study
The theoretical framework that I used to guide this study was the social-ecological
model (SEM). The SEM, developed by Bronfrenbrener and McLeroy, provides insights
into the interrelationships between an individual and population-level factors that
influence behavior (Bronfenbrenner, 1979; McLeroy et al., 1988). The social-ecological
model is a systems model with five bands of influence; the individual level lies at the
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core of the model, surrounded by the other bands of influence i.e., the interpersonal,
organizational, community, and policy levels (McLeroy, et al., 1988). This conceptual
framework has been adopted by several public health organizations including the CDC to
develop health promotion and disease prevention because of its multilevel approach to
facilitate behavior change and promote health outcomes (Glanz et al., 2015). Research
demonstrates that SEM has also been adapted in cancer-specific multilevel interventions
including cervical and colorectal cancer screening (Daley et al., 2011; Joseph, et al.,
2011; Smith & Brawley, 2014) as well as enhance communication and implement
programs that support initiatives for breast cancer survivors (Buchanan et al., 2013).
Additionally, this model has been applied to guide the development of public health
programs that optimize the health of an individual before and after a cancer diagnosis.
The SEM relates to the study approach and research questions in this study
because it is a useful framework for understanding the determinants i.e., the array of
individual- and contextual-level factors that influence endometrial cancer survival
outcomes. At the individual level, SEM is useful in describing biological factors and
behaviors associated with increased risks such as tumor histology and variations in
genetic susceptibility, and comorbid conditions (Moore et al., 2015); as well as
demographic characteristics i.e., age, race/ethnicity, and economic status. Studies have
shown that women at lower income levels were more likely to present with advancedstage disease and were less likely to receive surgery (hysterectomy) as their primary
treatment thus contributing to poorer survival rates (Kish et al., 2014; Madison et al.,
2004; Williams et al., 2016). Consequently, at the interpersonal level, SEM can be
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adapted by health care workers, patient navigators, and social support systems to
influence individual behaviors. For instance, in delivering interpersonal messages that
encourage an individual to seek medical care, especially predisposed individuals or those
with a family history of disease. In addition, SEM can be adapted to promote initiatives
that improve access to quality health care services among low-income women to facilitate
earlier diagnosis and high-quality treatment. SEM would also prove an effective approach
for influencing characteristics of organizations, institutions, and implementing policies
that improve endometrial cancer survival outcomes.
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Figure 1
Modified Social Ecological Model for Endometrial Cancer Risk among U.S. Women
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Nature of the Study
This study was a quantitative, retrospective, cross-sectional study to ascertain the
determinants of endometrial cancer survival disparities of women in the United States.
Specifically, this observational study was a secondary data analysis of epidemiologic data
collected by the National Cancer Institute’s Surveillance Epidemiology and Ends Results
Program. The data that I obtained were the most current data available on incidence and
survival of endometrial cancer cases diagnosed from 2007 to 2016. I used study variables
including independent variables, dependent variables, and covariates to address the
research questions and hypotheses. The main outcome variables (dependent variables)
were endometrial cancer stage at diagnosis, treatment, and survival. The key independent
variables for this study were race/ethnicity, insurance, histologic subtype, and tumor
grade. Other variables included in analyses to account for potential confounding effects
were women’s age at diagnosis and marital status.
I extracted all data using the 8.3.5 SEER*Stat Software (National Cancer
Institute, 2019). I conducted statistical analyses using the IBM SPSS version 25 software
application. I used multilevel logistic regressions for the analysis of racial/ethnic
disparities in late-stage diagnosis and adjustment made for potential confounders. I used
multivariate cox proportional hazards model to examine the influence of determinants on
endometrial cancer survival measured as 5-year survival rates and reported as Hazard
Ratio (HR). All hypothesis tests were two-tailed. I set the significance level at p < .05.
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Literature Search Strategy
I conducted a literature review of peer-reviewed journal articles and seminal
literature with a primary focus on disparities in survival for women treated for cancers of
the uterine corpus for this study. To provide a complete, exhaustive summary of current
evidence relevant to this topic, I examined articles published between the years 1980–
2021, ensuring the citation of primary sources. My search included multiple electronic
databases including MEDLINE, CINAHL, NCI, ProQuest, and PubMed. I also retrieved
relevant articles from Google Scholar and EBSCO accessed through the Walden
University Library. In addition, I conducted a search in the Walden dissertation database
although no relevant articles related to my research topic was found. I used the following
keywords and phrases for searches: endometrial cancer, uterine cancer, late-stage
cancer, diagnosis, incidence, mortality, survival, racial/ethnic disparities, histology,
socioeconomic status, SEER, and insurance. The literature search strategy that I used was
comprehensive and I reviewed articles on endometrial cancer survival disparities,
including epidemiology, disease and patient characteristics, and other multilevel factors
that can influence endometrial cancer diagnosis, treatment, and survival outcomes.
Literature Review
This review includes the current body of literature that is relevant in identifying
sociodemographic, pathological, and treatment factors that contribute to disparities in
endometrial cancer survival.
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Endometrial Cancer: Symptoms, Diagnosis, and Treatment
Endometrial cancer is the most common type of cancer that affects the female
reproductive organs, specifically the endometrium, which is the lining of the uterus.
According to the American Society of Clinical Oncology (ASCO, 2017), there are
generally two types of this cancer: (a) endometrial cancer (Type 1), the most common, it
grows slowly and is found only in the uterus; (b) endometrial cancer (Type II), spreads
more quickly and affects other parts of the body. One of the earliest symptoms observed
in women diagnosed with endometrial cancer is abnormal uterine bleeding (ASCO,
2017). Premenopausal women have reported irregular menstrual bleeding, spotting, and
bleeding between menstrual periods, non-bloody vaginal discharge, and bleeding after
menopause for postmenopausal women (Matteson et al., 2018). Patients with advancedstage disease may have symptoms such as abdominal or pelvic pain, abdominal
distension, sudden weight loss, and changes in bowel or bladder functions (ASCO, 2017).
Based on the report by Howlader et al. (2017) on patients diagnosed with endometrial
cancer between 2008 and 2014, endometrial cancer diagnosed at an early stage has a
reported survival rate of 96%. For women with symptoms suspicious for endometrial
cancer, or those with strong family history or genetic predisposition, the standard
diagnostic evaluation performed to confirm an endometrial cancer diagnosis includes a
pelvic ultrasonography, endometrial biopsy, dilatation and curettage (D&C), or a CA-125
blood test to test if cancer has spread (Bagaria et al., 2017; Tzur et al., 2017). A metaanalysis of studies examining the efficacy of several endometrial sampling devices
including the Pipelle aspiration catheter showed that all devices analyzed had a high
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specificity rate of 98% for endometrial cancer and endometrial hyperplasia (Dijkhuizen et
al., 2000). Currently, endometrial biopsy remains the gold standard, the most accurate
and commonly used test in the diagnostic evaluation for endometrial cancer, particularly
in postmenopausal women (Burke et al., 2014).
After a confirmed diagnosis of endometrial cancer, it is important the stage of a
tumor is determined. In 1988, the International Federation of Gynecologists and
Obstetricians (FIGO) formally recommended surgical staging as part of the initial
treatment for endometrial cancer (AJCC, 2017). Staging informs doctors of how far out
the disease has spread in the body and helps determine how best to treat the disease. The
American Cancer Society (2014a) classifies endometrial cancer from Stage I through IV;
localized/early stage disease are depicted with lower numbers, while a higher number
such as Stage IV represents advanced stage of disease i.e., cancer has spread to other
parts of the body. The most recent AJCC Cancer TNM staging classifies endometrial
cancer based on three factors: (a) the size of the tumor (T) i.e., how far the cancer has
grown into the uterus, and adjacent organs, (b) the spread to adjacent lymph nodes (N) in
the pelvis or around the aorta, and (c) the spread (metastasis) to distant sites (M) i.e.,
lymph nodes or organs in other parts of the body (AJCC, 2017). Hence the acronym T, N,
and M characteristically used in cancer staging. The American Cancer Society (2014)
suggested that current treatment options for endometrial cancer include surgery where in
most cases the cervix and uterus are removed (total hysterectomy), as well as
both ovaries and fallopian tubes (salpingo-oophorectomy). Lymph nodes and other tissue
may also be removed and tested for cancer. In a process known as surgical staging, the
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pathological stage of the tumor can be determined after examining tissue removed
following an operation (AJCC, 2017). Staging is used by a doctor to decide if additional
treatment, such as chemotherapy or radiation therapy, is needed.
Prevalence, Incidence, and Mortality
Endometrial cancer is the fourth most diagnosed and the seventh most common
cause of death among women, with an estimated 772,245 diagnosed cases in the United
States as of 2016 (Cronin et al., 2018). According to U.S. Cancer Statistics (2014), there
has been a decline in overall cancer incidence in the United States. However, incidence
rates for endometrial cancer have continued to increase over time. Based on incidence
and mortality data obtained from the CDC’s National Program of Cancer Registries
(NPCR), the SEER program, and mortality data from the National Vital Statistics
System, endometrial cancer incidence rates increased 0.7% per year from 1999–2015,
and death rates increased 1.1% per year from 1999–2016 (Henley et al., 2018). Based on
2013–2017 cases, the prevalence of endometrial cancer in the United States was 27.8 per
100,000 women per year; while the number of deaths was 4.9 per 100,000 women per
year based on 2014–2018 cases (NCI SEER, 2020). In 2017, there were an estimated
793,846 women diagnosed with endometrial cancer in the United States. In 2020, it was
estimated that there would be 65,620 new cases of uterine cancer and an estimated 12,590
deaths from the disease (NCI SEER, 2020). The risk lifetime for developing endometrial
cancer is about 3.1%, particularly among U.S. women aged 45–74 (NCI SEER, 2018).
Although incidence rates for endometrial cancers are rising across all racial/ethnic
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groups, there continues to be a widening disparity in endometrial cancer survival between
races and ethnicities.
Several studies using large databases have shown the evident disparity in
incidence and mortality of endometrial cancer among different races. Racial/ethnic
disparities in survival is more prominent in endometrial cancer compared to other
gynecologic cancers including ovarian and breast cancer (Cronin et al., 2018). Black
women experience an 80% higher mortality rate compared to White women (DeSantis et
al., 2016). Siegel et al. (2014) conducted an analysis examining 5-year survival rates in
endometrial cancer and found a significant difference of about 22% in survival for Black
women (64%) compared with White women (86%). As demonstrated by Henley et al
(2018), non-Hispanic White (NHW) women and non-Hispanic Black (NHB) women
report higher endometrial cancer incidence rates (27 cases per 100,000) than any other
racial/ethnic groups (19–23 per 100,000), while endometrial cancer mortality rates are
much higher among Black women (nine per 100,000) than among other racial/ethnic
groups including White women (four to five per 100,000). Henley et al. (2018),
comparing incidence and mortality rates among White and Black women in the U.S.
found that Black women had a decreased risk of being diagnosed with endometrial cancer
compared to White women (24.8 versus 26.3 new cases/100,000 per year) but a
significantly higher risk of death from disease (8.1 versus 4.2 deaths/100,000 per year).
Research has shown that observed disparities may be due to significantly higher
incidence of advanced uterine corpus cancers and aggressive histologic subtypes such as
serous and clear cell adenocarcinoma, malignant mixed Mullerian tumors and sarcomas
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in Black women (Collins et al., 2014; Mahdi et al., 2016; Rauh-Hain et al., 2018). A
recent study examining trends in endometrial cancer incidence from 2000 to 2011 found
an even larger gap in incidence with NHB women representing an excess incidence of
endometrial cancer for aggressive histologic subtypes (Cote et al., 2015). The 5-year
cause-speciﬁc survival observed in this study was significantly less in Black women than
White women (Cote, et al., 2015). Due to a lack of available data, there are currently
limited studies examining endometrial cancer mortality rates in Asian and Hispanic
women. However, results from a few studies suggest that survival rates in Asian and
Hispanic women are similar to or better than those of White women (Mahdi et al., 2014).
An understanding of incidence, mortality, and differences in survival can contribute
significantly to additional research needed to address disparities in endometrial cancer
outcomes.
Determinants of Endometrial Cancer Survival Disparities
Literature suggests that the reasons for disparities in endometrial cancer survival
outcomes are multifactorial. They include the histopathologic, socioeconomic, and
treatment factors discussed below.
Histopathologic Factors
Endometrial cancer stage at diagnosis, histology type, and grade of disease have
been found to be important prognostic factors for survival (Fader et al., 2016; Long et al.,
2013; Morice et al., 2016; Smotkin et al., 2012). Based on the statistics from the National
Cancer Institute, SEER 18 Data 2009–2015, the relative 5-year survival rates by
endometrial cancer stage are as follows: 95% for Stage I and II cancers (localized), 69%
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for Stage III and IVA cancers (Regional), 16.8% for Stage IVB (Distant), and 52.9% for
unknown (NCI SEER, 2018). When endometrial cancer is diagnosed at an early localized
stage, the 5-year survival rate is about 95%; however, only 54% of Black women are
diagnosed at this stage compared to 69% of White women (ACS, 2014b). Therefore, an
important determinant of endometrial cancer survival is stage at diagnosis. Studies have
shown that women with advanced stage at diagnosis of endometrial cancer, especially
African American women, also present with other characteristics such as older age,
higher tumor grade, and more aggressive histology (Madison et al., 2014; Oliver et al.,
2011; Smotkin et al., 2012). Hence, the need for histopathological factors to be controlled
for in modeling endometrial cancer disparities. Even after adjusting for these predictors,
Madison et al (2014) found that African American women are still more likely to present
with advanced-stage disease and have poorer prognoses.
The reasons for the higher mortality rates observed among Black women
diagnosed with endometrial cancer are not completely understood. Numerous studies
have shown that Black women are more likely to be diagnosed with later stage, higher
grade disease, and with poorly-differentiated and aggressive non-endometrioid histologic
types (Sheikh et al., 2014; Wartko et al., 2013). They also report less favorable survival
outcomes regardless of histologic type, stage or grade of disease. Research conducted by
Cote et al. (2015) using population-based SEER cancer registry data to examine
endometrial cancer incidence and mortality disparities by race/ethnicity and tumor
histologic subtype showed that compared to White women, Black women had
signiﬁcantly low incidence rates for low-grade endometrioid subtypes (well-differentiated
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or moderately differentiated tumors) but higher incidence rates for high-grade
endometrioid subtypes (poorly differentiated, undifferentiated, or anaplastic tumors).
While these authors highlighted underlying complex biological pathways involved in
carcinogenesis as a possible explanation, Black women experience poorer survival
outcomes compared to other races, even when analyzing patients with similar stage of
disease, tumor grade, and histologic subtypes.
Race/Ethnicity
Race/ethnicity is an important contributor to health disparities as it significantly
impacts the diagnosis, treatment, and survival outcomes of patients with endometrial
cancer. The effect of race/ethnicity on disparity outcomes suggest the trend in incidence
and mortality of endometrial cancer in the United States over the last decade is quite
distinct; African Americans have a 30% decreased incidence and a mortality rate 80%
higher when compared to Whites (Farley et al., 2007). According to the NCI SEER
2013–2017 statistics, White women had the highest incidence rate of endometrial cancer
per 100,000 women per year (28.3), followed by Black women (27.9), Hispanic (24.6),
Asian/Pacific Islander (21.7), and American Indian/Alaska Native (19.9) women .
Compared to other races, Black women had the highest mortality rate of endometrial
cancer (8.7), followed by White (4.5), Hispanic (4.1), American Indian/Alaska Native
(3.5), and Asian/Pacific Islander (3.2) women (NCI SEER, 2020).
Jemal et al. (2010) found that Black patients diagnosed with endometrial cancer
are 2.5 times more likely to die from the disease compared to White patients. More recent
studies have also shown similar disparate incidence trends of endometrial cancer. A
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previous study based on incidence data from 1996 to 2006 found a considerable gap in
incidence with African American women representing only 6.8% of all endometrial
cancer cases and 17.4% of Type II endometrial cancers .i.e. poorly differentiated or highgrade tumors (Duong et al., 2011). This result is consistent with that of a previous study
conducted using data from the California Cancer Registry database (CCR) to identify
women with Type II endometrial cancers from 1998 to 2009, suggesting Black women
have a higher incidence of more aggressive histologic subtypes even among a group of
women with high‐grade endometrial cancer and experience worse disease‐specific
survival even after adjusting for potential confounding factors such as age, stage at
diagnosis, histologic subtype, tumor grade and type of treatment (Baskovic et al., 2018).
Rauh-Hain et al (2018) examined racial differences in treatment and survival
using 1992-2009 SEER-Medicare linked data comprised of African American and White
women with high-grade endometrial cancer. Results of study analysis showed that White
women were more likely to receive definitive surgical treatment for endometrial cancer
(88.7% versus 76.8%) than African American women. African American women also
reported lower cancer-specific and all-cause survival compared with White women.
However, there was no significant difference in disease-specific survival after adjusting
for tumor characteristics, treatment, comorbidities, and sociodemographic factors. In
examining racial differences in endometrial cancer outcomes, most of the reviewed
studies have mainly focused on incidence and survival comparisons between African
American and Caucasian subpopulations. Very few studies have been carried out on
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Hispanics or Asians, two of the largest and fastest-growing minority ethnic groups in the
United States.
The study conducted by Cote et al. (2015) was based on a study population that
included Hispanic and Asian patients. Study results showed that Hispanic and Asian
women have incidence and 5-year relative survival rates equal to or lower than White
women even after controlling for stage of disease and histologic subtype. However, more
research is needed to explore endometrial cancer incidence and survival outcomes among
Hispanics and Asians compared to non-Hispanic Whites (NHWs) and non-Hispanic
Blacks (NHBs).
Age
Age is an important risk factor for cancer, but data regarding whether patient age
at diagnosis can contribute to disparities in endometrial cancer survival are conflicting.
Cancer can be considered an age-related disease as the incidence of most cancers
increases with age (White et al., 2014). In research from Singh et al. (2016), most
endometrial cancer cases are diagnosed in post-menopausal women i.e. women over the
age of 50. The average age at diagnosis for endometrial cancer is 60 years; the disease is
not common in women younger than 45 (Singh et al., 2016). For several reasons, cancer
research studies have demonstrated that age at diagnosis is associated with poorer
prognosis and worse health outcomes especially among older persons over the age of 45
(Ory et al., 2014; White et al., 2014). Based on SEER (2018), 40% of women diagnosed
with endometrial cancer are aged 65 or older, and 67% of deaths from endometrial cancer
occur in women over 65.
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Duska et al. (2016) found that older women are more likely to die of endometrial
cancer compared with younger patients due to late-stage diagnosis, or more aggressive
tumor biology. The presumed late-stage diagnosis common among older women may be
due to social and cultural influences including financial concerns, educational barriers
that limit access to health-related information, increasing risks of comorbidities that could
cause reluctance to offer definitive surgery treatment to older patients, and complications
of invasive therapies such as surgery and chemotherapy (Long et al., 2013; Madison et
al., 2004; Ory et al., 2014). According to Long et al. (2013), age limits younger women
from most government-funded insurance plans, thus limiting access to health care and
contributing disproportionately to increased rates of advanced disease diagnosis
particularly among minority populations. Age is often included as a predictor in survival
analysis to account for its possible confounding effects. A meta-analysis investigating age
at menopause and risk of developing endometrial cancer found that late menopausal age
was associated with an increased risk of endometrial cancer (Wu et al., 2019); while the
performed dose-analysis showed a statistically significant positive association when age
at menopause was greater than 46.5 years old.
Insurance Status
Insurance status is also an important contributor to endometrial cancer survival
disparities. Measures such as income, education, occupation, and insurance status are
typically used in public health research as proxy variables to estimate socioeconomic
status (SES) for patients (Krieger et al., 1997; Montgomery et al., 2000). Previous studies
have shown that uninsured and Medicaid insured patients with common cancers in the
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United States have poorer health outcomes including more advanced disease, higher
mortality, and are less likely receive cancer-directed therapy than patients with private
insurance (Grant et al., 2016; Niu et al., 2013; Rosenberg et al., 2015). Studies have also
established that uninsured and Medicaid insured patients diagnosed with endometrial
cancer have lower survival than do patients with private insurance or Medicare, even
after adjustment for other factors (Dolly et al., 2016; Fader et al., 2016; Fedewa et al.,
2011).
Fedewa et al (2011) based on data from the National Cancer Database (NCDB)
examined the impact of race and insurance on endometrial cancer survival. African
American and Caucasian patients without private health insurance experienced worse
survival outcomes thus contributing to endometrial cancer survival disparities. A
retrospective study based on the Rush University Medical Center Cancer database
examined patients diagnosed with and/or treated for endometrial cancer from 2005 to
2012 and found that although majority of the patients had insurance (Private insurance
49.6%; Medicare 42.1%; Medicaid 4.4% ), patients with Medicare and Medicaid
insurance experienced significantly longer interval time to treatment compared to patients
with private insurance. Study analysis showed that Medicaid patients had the longest
treatment interval with a mean treatment delay of 78 days, followed by Medicare patients
with 54 days; patients with private insurance had the shortest interval at 38.4 days which
was found to be clinically significant (p < 0.001) even when stratified by stage of disease.
In addition, longer interval time from diagnosis to treatment was associated with
decreased endometrial cancer survival. This study supports findings by Elit (2015),
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whose analysis of a Canadian population also found that a delay in treatment was
associated with a decrease in overall survival for patients with uterine cancer. Although
the causes of these delays are likely multifactorial, the findings from these studies are
significant because Medicaid beneficiaries in the United States include a
disproportionately high percentage of minorities, especially Blacks (21%) and Hispanics
(25%), although a higher percentage of total Medicaid beneficiaries are White (40%)
(Kaiser Family Foundation, 2013). It is evident that individuals with Medicaid or without
health insurance are more likely to present with advanced-stage disease at diagnosis as
they tend not to seek timely treatment or may experience increased interval wait time
from diagnosis to treatment.
Marital Status
There is a well-established association between marital status and survival in
cancer patients; married patients compared to unmarried patients have decreased
mortality in several malignancies such as prostate, breast, cervical and colon cancers
irrespective of age, tumor grade, and disease stage (Hanske et al., 2016; Hinyard et al.,
2017; Liu et al., 2019; Tyson et al., 2013; Wang et al., 2011). Few studies have examined
the impact of marital status on survival in patients with endometrial cancer. A study
based on 1991-2010 SEER data was used to assess the effect of marriage on survival
outcomes for women diagnosed with uterine cancer (Lowery et al., 2015). Study results
suggest that as opposed to widows, married women benefit significantly from
personalized care and social support from their partners and thus have improved survival

25
outcomes. More studies are needed to examine the effect of marital status as a prognostic
factor for the survival of endometrial cancer patients.
Treatment
Treatment factors have been suggested as a contributor to endometrial cancer
survival disparities. Invasive treatments such as surgery, radiation therapy, and systemic
therapy are often recommended by clinicians in the management of endometrial cancer.
The standard treatment for most endometrial cancer cases is surgery, typically
hysterectomy (removal of the uterus, cervix, and bilateral fallopian tubes and ovaries). In
most cases, surgery alone may be curative for early-stage, low-grade disease; however,
adjuvant therapy such as chemotherapy and/or radiation therapy may be recommended
for patients with advanced disease and less favorable clinicopathologic features. Several
studies have examined survival outcomes of surgical and adjuvant treatment on
endometrial cancer patients. In terms of age, population-based studies conducted over the
last decade suggest that there is a difference in treatment received, specifically in
performing surgery for older patients with endometrial cancer. Two different SEER
analyses demonstrated that older patients with endometrial cancer were less likely to
receive surgical treatment, hysterectomy, and thus experienced poorer survival outcomes
(Ahmed et al., 2008; Wright et al., 2011). Duska et al. (2016) suggest that older women
are more likely to have high-grade uterine cancer tumors, poor histology, and advanced
disease; consequently, require adjuvant treatment and/or surgery. In another study
evaluating survival in endometrial cancer patients administered similar surgery and
adjuvant radiation treatment (Gayar et al., 2011), elderly patients (≥ 75 years) diagnosed
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with FIGO stage I–II endometrial cancer were found to have poorer histopathological
features, and worse disease-specific and overall survival than younger patients
(< 75 years). A more recent study by Rauh-Hain et al (2015) using data from the National
Cancer Database found that elderly women with advanced-stage (stage III or IV) disease
were less likely to be treated with surgery, chemotherapy, or radiation.
While examining the effect of race on disparity in treatment and survival, it has
been shown that African American women with endometrial cancer have higher cancerspecific mortality. Black women with endometrial cancer are less often to receive
surgical treatment at every stage and grade of disease (Rauh-Hain et al., 2015). An
analysis of data from the National Cancer Database (NCDB) examined Stage I-III
endometrial cancer patients who underwent surgery, African American women were less
likely to receive postoperative radiation therapy and are more likely to die of endometrial
cancer compared to Caucasians (Cho & Viswanathan, 2018). Rauh-Hain et al. (2018)
also using NCDB data from 20042014 examined trends over the past 10 years in
treatment and survival among different racial groups including White, Black, Asian, and
Hispanic women diagnosed with endometrial cancer. Compared to other racial groups,
Hispanic women with high-grade endometrial cancer were less likely to undergo surgery,
lymphadenectomy (80.7% versus 74.5%). In addition, Black women diagnosed with
endometrial cancer had lower five-year survival than other racial groups.
Definitions
This section reviews definitions of study variables included in analysis. The
variables examined in this study include the outcome variables: endometrial cancer stage
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at diagnosis, treatment, and survival. The key independent variables for this study are
race/ethnicity, histologic subtype, tumor grade and insurance. Other potential covariates
included in study analysis are age at diagnosis and marital status.
Stage at diagnosis
For the purpose of this study, staging refers to the process of finding out how
much cancer is in a person’s body and where it is located (ACS, 2018). Hence, it can be
used to determine the stage of a person’s cancer. The SEER database grouping of
endometrial cancer is based on how far the cancer has spread; specifically, localized,
regional, and distant stages (NCI SEER, 2013). Stage I and II endometrial cancers are
localized and have not spread outside the uterus (AJCC, 2017). Stage III and IVA
endometrial cancers that have spread from the uterus to nearby tissues, organs or lymph
nodes are said to be regional (AJCC, 2017). Distant cancers include Stage IVB cancers
and have spread to the lungs, livers or bones (AJCC, 2017). For this study, the variable
“stage at diagnosis” was classified as “Non-advanced stage” and “Advanced stage”. Nonadvanced /Early-stage endometrial cancer was for localized cases, while it was
dichotomized as advanced-stage disease for regional or distant cancers.
Survival time
Survival time was defined as the date of endometrial cancer diagnosis to the date
of endometrial cancer-cause specific death or the cut-off time for follow-up (NCI SEER,
2018). For patients who were still alive, data were censored based on the date of the last
follow-up visit.
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The event in the survival analyses was endometrial cancer-cause specific death within 5
years of endometrial cancer diagnosis. The survival outcome was measured as 5-year
endometrial cancer-cause specific mortality and reported as Hazard Ratio (HR).
Treatment
According to the National Cancer Institute, treatment can be described as a
detailed plan with information about a patient’s disease, the purpose of treatment, the
treatment options for the disease including possible side effects, the expected length of
treatment, and potential plans for follow-up care after treatment ends (NCI, 2018). Data
for the primary treatment of surgery were obtained from SEER records. According to the
American Cancer Society (2018), surgery (hysterectomy) to remove the uterus is
typically the primary treatment for uterine corpus cancers. However, in some cases,
depending on cancer subtype and stage of disease, adjuvant therapy such as
chemotherapy, radiotherapy, or hormone therapy may also be used (ACS, 2018).
For study analysis, treatment information was measured as “No surgery”, “Surgery”.
Other individual-level factors obtained from SEER included tumor
histopathologic characteristics, race/ethnicity, insurance status, age at diagnosis, and
marital status.
Histologic subtype
Histological classification of cancer subtypes is based on the type of tissue in
which the cancer originates and by primary site, or the location in the body where the
cancer first developed (AJCC, 2017). Data coding in SEER for tumor site, grade, and
histology was classified in accordance with the third edition of the International
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Classification of Diseases for Oncology [ICD-O-3] (Jack et al., 2000). For this analysis,
major tumor histologic subtypes was categorized as follows: “endometroid", “uterine
carcinosarcoma”, “serous carcinoma”, “clear-cell carcinoma” and “other” (includes
squamous cell carcinoma, small cell carcinoma, transitional carcinoma). Endometroid
(also called endometrial adenocarcinoma) is the most diagnosed histologic subtype; they
are low-grade tumors and have a high cure rate (Jack et al., 2000). Serous carcinoma is
the second most common type of endometrial carcinoma; they tend to be more aggressive
and are often diagnosed at advanced stage of disease (Jack et al., 2000). Uterine
carcinosarcoma (CS), is also referred to as malignant mixed mesodermal
tumors or malignant mixed mullerian tumors (MMMTs), make up about 3% of
endometrial cancer cases (Murali et al., 2019).
Furthermore, studies have shown that non-Hispanic Black (NHB) women suffer
worse survival outcomes as they are more likely to be diagnosed with aggressive
histologic subtypes, such as serous carcinomas, clear-cell carcinomas, and
carcinosarcomas compared with other racial/ethnic groups (Long et al., 2013). Uterine
sarcomas, which include uterine leiomyosarcomas and endometrial stromal sarcomas,
develop in the muscle layer (myometrium) or supporting connective tissue of the uterus
(Murali et al., 2019), were excluded from this analysis.
Tumor grade
A tumor is described based on how abnormal the cancer cells and tissue look
under a microscope and how quickly the cancer cells are likely to grow and spread (NCI,
2018).
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Grading systems vary for each type of cancer and are used to inform treatment plans and
determine disease prognosis. Grade is based on how different endometrial cells tumor
cells differ from normal cells. Grade is usually grouped between 1 and 3. The lower the
grade, the better the prognosis (SEER 2018). For endometrioid tumors, grade can either
be 1, 2 or 3. However, serous carcinoma or clear-cell carcinomas are usually graded 3
and indicate a worse prognosis (Jack et al., 2000). Endometroid tumors can also be
further classified as “low-grade” endometrial cancers (for well-differentiated to
moderately differentiated tumors), while carcinosarcomas, serous carcinomas and clear
cell carcinomas are classified as “high-grade” endometrial cancers (for poorly
differentiated to undifferentiated tumors). Endometrioid adenocarcinomas are type 1
endometrial cancers that generally present as low-grade tumors. They occur as a result of
excess estrogen in the body; they look like normal cells, are slow-growing, not aggressive
and less likely to spread (Soslow, 2013). Type II tumors are high-grade endometrial
carcinomas such as carcinosarcomas, serous carcinomas, and clear cell carcinomas.
Setiawan et al (2013) described type II tumors as poorly differentiated tumors, estrogenindependent, more aggressive, and present with poorer prognoses than type I tumors.
For this analysis, the classification of tumor grade was based on the 7th edition of
the American Joint Committee on Cancer (AJCC) cancer staging manual (Edge &
Compton, 2010); the variable tumor grade was coded as “well-differentiated”,
“moderately-differentiated”, “poorly-differentiated”, “undifferentiated”, with all other
histologic subtypes categorized as “unknown.”

31
Race/ethnicity
Race/Ethnicity was defined as Non-Hispanic White (NHW), Non-Hispanic Black
(NHB), Hispanic, Non- Hispanic Asian/Pacific Islander (NHAPI), and Non-Hispanic
American Indian/Alaska Native (NHAIAN).
Insurance
The insurance variable was defined as the type of insurance reported by patients
at the time of diagnosis: “Insured” (Medicare and private insurance), “Medicaid”, and
“Uninsured”. Private insurance includes fee-for-service plans, managed care plans, health
maintenance organizations, VA/TRICARE/Military/Public Health Service, and preferred
provider Organizations (NCI SEER, 2013). Medicaid includes managed care plans,
public health service insurance, and other state-administered insurance programs (NCI
SEER, 2013); Medicare includes insurance administered through managed care plans,
and Medicare with supplemental coverage (NCI SEER, 2013). Previous research
conducted by Niu et al (2013) demonstrated an association between stage at diagnosis
and insurance among women with uterine cancer; as patients who were uninsured or had
Medicaid as opposed to private insurance, were more likely to present with advancedstage disease, even after adjusting for other factors.
Age at diagnosis
The measure “Age at diagnosis” was categorized into five groups. They are 18-45
years, 46-55 years, 56-65 years, 66-75 years, and 76 years and older.
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Marital status
In the SEER dataset, self-reported data on marital status was documented at the
time of diagnosis of patients. For analysis, marital status was grouped as “single” (never
married), “married”, “separated/divorced”, and “widowed”. Where patients do not
specify marital status, cases will be grouped as “Unknown”.
Assumptions
This study was conducted based on the assumption that all information abstracted
from the SEER database was accurate in its representativeness of data collated from a
coordinated system of cancer registries located across the United States. Furthermore, it
was assumed that although individual records could not be reviewed to ensure accuracy
of the data, source registries ensured that all the individuals who consented to participate
in the study and met the inclusion criteria, provided complete information that was deidentified in the SEER database. Utilizing the SEER database was necessary for the
context of this study because it generates incidence, mortality, treatment, and survival
data for cancer subtypes, including information on histopathology and its implications
across demographic groups, geographic regions, and time (Duggan, Anderson, Altekruse,
Penberthy, & Sherman, 2016). In addition, it was the assumption that based on the
research questions and hypotheses, the SEER dataset was the best fit for this study, in
terms of the selected patient population, large sample size, and available data on
measures of the variables of interest including predictors, outcomes, and potential
confounders.
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Scope and Delimitations
The specific aspects of the research problem addressed in this study aimed at
elucidating the factors associated with disparities in endometrial cancer survival among
US women; while focusing specifically on multiple factors have been linked including
differences in race/ethnicity, stage at diagnosis, tumor histopathology, insurance, and
treatment type. For this study, the main outcome measures were endometrial cancer stage
at diagnosis, treatment, and survival. This specific focus was selected because signiﬁcant
disparities in endometrial cancer outcome persist based on race/ethnicity, socioeconomic
status, and other factors. A report by Siegel, Miller& Jemal (2015) showed that 5-year
all-stage survival for White women with endometrial cancer was 84%, compared with
61% for Black women. Previous studies have elucidated that factors such increasing age,
higher tumor grade, more aggressive histology, and insurance are associated with
advanced stage at diagnosis; particularly among African American women even after
adjusting for these predictors (Cote et al., 2015; Fader et al., 2016; Niu et al, 2013).
Hence the need to identify the factors associated with disparities in stage at diagnosis and
receipt of surgery; specifically, how these determinants inﬂuence survival of women with
endometrial cancer.
This study was based on a large nationwide population of uterine cancer patients
diagnosed between 2007 and 2016 in the SEER Database. The study population included
women aged 18 and older diagnosed with endometrial cancer in the United States.
However, there were some limitations associated with using the SEER dataset. One of
which was ensuring that all data reported on the SEER database was complete and
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accurate. It was difficult to evaluate the data collection method used by source registries
to obtain personal information, as well as patient and disease characteristics; thus, a
major limitation of this study. In addition, since this was an observational study, a causal
relationship could not be established between race/ethnicity, tumor subtype, insurance,
treatment, stage at diagnosis and survival based upon the possible findings. Also, survival
outcome could not be fully evaluated as the collected data did not distinguish whether
initial treatment received was curative. Finally, another potential limitation of this study
was not examining other potential risk factors that have been known to be associated with
increased risk of most gynecologic cancers. Till date, SEER does not collect individuallevel data on health information such as socioeconomic status (SES), smoking, alcohol
consumption, educational level, income level, obesity, and co-morbidities; therefore,
these potential confounding factors could not be controlled for during the data analysis.
This was a retrospective study consisting of secondary data obtained from the
SEER National Cancer Database of women diagnosed with endometrial cancer between
2007 and 2016. The target population examined included a group of women aged 18
years and over diagnosed with Stage I - IV endometrial cancer. Using the SEER program
was a potential strength of this study, with regard to representativeness and
generalizability to the U.S. population. The population-based data was obtained from 18
Cancer Registries and contains information on cancer incidence, diagnoses, treatment and
survival for approximately 30% of the U.S. population (Park, Lloyd, Decker, Wilson, &
Yu, 2012). Duggan et al (2016) also highlight other strengths of the SEER data including
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large numbers of cases, reporting of cancer-specific outcomes, and the lengthy period of
data collection largely due to patient follow-up.
Significance, Summary, and Conclusions
This chapter introduced the study, stated the problem statement and purpose of
the study, presented a detailed background of the study while highlighting the research
questions and hypotheses, as well as the theoretical foundation on which the study was
based. It also provided an exhaustive review of the current literature and research related
to endometrial cancer survival disparities among women in the United States. In addition,
information on assumptions, limitations, and importance of the study was also discussed.
Data obtained from the SEER program was used to answer the research questions and
address the gap in literature on what determinants contribute to survival disparities in
women diagnosed with endometrial cancer in the United States.
Currently, the reason for survival disparities in women with endometrial cancer is
multifactorial; however, age, race/ethnicity, histologic subtype, treatment, insurance, and
other determinants have been identified in the literature as contributory factors for
advanced stage endometrial cancer diagnosis and poorer survival (Long et al., 2013;
Smotkin et al., 2012; Niu et al, 2013). Due to the complexity of interactions between
potential risk factors, there is a need for continued research in this area. By identifying
determinants of endometrial cancer survival, this study may highlight the potential
influence of socioeconomic, histopathologic and treatment factors on survival disparity.
Consequently, this study may encourage the development of effective endometrial cancer
prevention and health promotion programs aimed at improving health outcomes in
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women across the United States. Other potential contributions of this study include
advancement in health policies such as the Affordable Care Act to promote access to
healthcare services for women without adequate insurance, which is the case for a
disproportionate number of African American women and other minorities. The
implications for social change for this research include a better understanding of
disparities associated with advanced stage diagnosis, primary treatment received, and
endometrial cancer survival. Study findings could serve as a foundation for reducing the
gap in survival by increasing awareness and education among women regarding the signs
and symptoms of endometrial cancer and providing quality information on seeking
appropriate treatment.
Endometrial cancer is the most common gynecologic cancer among American
women (Siegel et al., 2013); incidence and mortality been shown to vary by race and
ethnicity with the highest rates reported among Black women (Edwards et al., 2014). The
current study updates knowledge about racial/ethnic disparities in endometrial cancer
diagnosis and survival based on most recent national-level cancer research data.
Identifying the determinants of endometrial cancer survival disparities will allow
government and non-governmental agencies apply more focused efforts aimed at
eliminating racial inequities and improving health outcomes. By expanding insurance
coverage and promoting equal access to medical care for all women especially those in
underserved communities will go a long way in decreasing mortality rates. Also,
encouraging continued cancer health disparities research will advance knowledge in this
discipline.
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Section 2: Research Design and Data Collection
Introduction
This section includes a description of the research design and data collection
methods utilized in this quantitative study. The purpose of this study was to examine the
determinants of endometrial cancer survival disparities in the United States. As stated in
Section 1, the purpose of this quantitative study was to explore histologic and
socioeconomic factors that contribute to disparities in mortality and survival of women
with endometrial cancer in the United States and identify ways to address these
inequalities.
This focus of this section is the quantitative research paradigm and the rationale
for this study. There is also a discussion on research methodology, the operationalization
for each variable, the data collection process and data analysis plan, a description of study
participants, as well as the inclusion and exclusion criteria used in the study. In addition,
biases and threats to validity were discussed to ensure data quality. Finally, the potential
confidentiality and ethical issues of the study were addressed.
Research Design and Rationale
This was a quantitative, cross-sectional study of a population-based cancer
registry database. The data obtained from the SEER database included diagnosed cases of
endometrial cancer reported from 2007 to 2016. The study population included three
dependent variables (endometrial cancer stage at diagnosis, treatment, and survival) and
four independent variables (race/ethnicity, histologic subtype, tumor grade, and insurance
coverage).Health information and sociodemographic factors such as women’s age at
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diagnosis and marital status were included in the analysis to account for possible
confounding.
The retrospective, cross-sectional design was the most appropriate design for this
study. Gordis (2009) described a cross-sectional study as an observational epidemiologic
design that measures the prevalence of health outcomes or determinants of health, or
both, in a population at a given point in time or over a short period. Cross-sectional
studies measure simultaneously the exposure and health outcome in a given population at
a certain time. The cohort of subjects selected from the SEER database were reported
cases of patients diagnosed with endometrial cancer selected based on the inclusion and
exclusion criteria set for the study. To examine multiple outcomes simultaneously, the
data for outcome variables i.e. endometrial cancer stage at diagnosis, surgery treatment,
and survival (measured from the date of diagnosis to date of death/ date of last follow-up
visit) were reclassified for analysis. In addition, cross-sectional data was used in this
study to evaluate the research question exploring 5-year survival among the varying
racial/ethnic groups of women diagnosed with endometrial cancer in the United States.
This was because the sufficiently large sample size could lead to statistically stable
estimates, making it easier to evaluate trends in these data. In addition, the cross-sectional
study design was suitable to effectively assess associations between multiple exposures
and multiple outcomes as demonstrated in this study.
In cross-sectional studies, data on study population has been collected and followup already completed before the onset of research. Therefore, regardless of the original
purpose for which the data were collected, data can be used in other secondary research
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analysis. Due to potential barriers such as time and resource constraints consistent with
the recruitment process in cross-sectional studies (Klebanoff & Snowden, 2018),
individual recruitment of participants for this study would have been extremely difficult.
Only a small sample size of endometrial cancer patients can be recruited in hospitals and
clinics based on medical records at a single point in time. There is a significant benefit in
having the NCI SEER database, an established cancer registry that reports information on
cancer incidence and survival in the United States.
Cross-sectional studies can be effective in advancing knowledge in cancer
research since data were typically made up of medical records that have already been
collected and stored in an electronic database. According to Sedgwick (2014), the goal of
observational study designs such as the cross-sectional study is to ensure that data were
collected from patients before, during, and after a clinical diagnosis and for a long period
so as to ensure all important data on disease etiology, incidence, treatment, follow-up,
and outcome is well documented. The SEER database is a unique resource that is relevant
for epidemiologic research as it allows researchers investigate disease trends, including
access to information on cancer screening, incidence, treatment, and survival outcomes
across demographic and socioeconomic groups. A major strength of the SEER cancer
registry is that it collects population-based data on individual cancer cases using
standardized methods of data collection to ensure validity and generalizability of study
outcomes (Howe et al., 2003). Using cross-sectional analysis of the SEER program for
this research study was relatively cheap, quick, and easy to perform due to the
expeditious process of accessing secondary data from the SEER database. Information on
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sociodemographic variables including cancer staging, treatment, and outcome available
on the SEER database makes this study a potential resource to advance knowledge in
cancer disparities research that examines endometrial cancer mortality trends.
Methodology
Population
I selected the target population from the SEER Program of the National Cancer
Institute (NCI), a population-based cancer registry database, and obtained demographic,
histopathological, diagnosis, treatment, and survival information for women diagnosed
with endometrial cancer from 2007 to 2016. The SEER*Stat 8.3.5 software was used to
extract cases from SEER 18 registry, generating the dataset from “Cervix Uteri” limited
to women with uterine corpus tumors. Eligible patients included Non-Hispanic White
(NHW), Non-Hispanic Black (NHB), Hispanic, Non- Hispanic Asian/Pacific Islander
(NHAPI), and Non-Hispanic American Indian/Alaska Native (NHAIAN) women
diagnosed with primary cancer of the uterine corpus; while patients diagnosed before the
age of 18, women who had in situ cancers, uterine sarcomas, or a previous history of
cancer or prior malignancy were excluded from the analysis.
Sampling and Sampling Procedures
For the purpose of this study, data on endometrial cancer cases in the United
States (N =130,375) were obtained from the original SEER datafile (NCI SEER, 1975–
2016) on the SEER database. Insurance status, one of the key variables, has only been
reported in the SEER database since 2007, so data extraction was limited to 2007–2016
to prevent missing data. The non-probability sampling method was the preferred
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technique for this observational study as it allowed for the use of inclusion and exclusion
criteria; the study population was limited to participants that met the eligibility criteria
thus allowing for a more focused outcomes research. Data obtained from SEER database
were readily accessible and available to answer the research questions posed in this study.
Since predictor, outcome, and potential confounding variables were readily available on
the SEER database, convenience sampling, a non-probability sampling method (Tyrer &
Heyman., 2016), was most appropriate for this retrospective study. Data analysis was
based on estimations and comparisons carried out on each variable. The sample size was
based on the total population of patients selected from the SEER database who satisfied
the inclusion criteria for the study. Specifically, the study sample comprised of
abstracted data distributed into several subgroups that share common characteristics such
as age, race or ethnicity thus ensuring a more representative sample of the population.
The study population included women between the ages of 18 and 80 years diagnosed
with endometrial cancer from different racial/ethnic population subgroups.
The NCI SEER database is the leading population-based resource for incidence
and survival data in the United States. This secondary data source includes information
on patient demographics, clinical information such as cancer diagnosis, treatment,
follow-up and/or death for approximately 30% of the U.S. population (Duggan et al.,
2016). The database is made up of information abstracted for several sources including
patient medical records, diagnostic imaging reports, chemotherapy clinics, and death
certificates (Duggan et al., 2016). Typically, cancer registry staff members abstract data
from the sources listed above using standardized data collection templates that are
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checked for accuracy and completeness, then edited, before reviewed information is
inputted into an electronic database. The SEER data is de-identified and available for
public use. Access to the SEER website (www.seer.cancer.gov) is unrestricted, and
information on the website may be copied without permission. However, approval is
necessary to view individual records such as cancer incidence data and mortality data. I
received authorization to access and use the SEER dataset for this research study, after a
signed permission form was submitted to SEER. Since the SEER data were publicly
available, approval was waived by the local ethics committee.
Power Analysis
The power of a statistical test is defined simply as the probability of rejecting a
null hypothesis when it is false (Jones et al., 2003). There are three interrelated
parameters that affect the statistical power of a study: the sample size, the alpha level,
and the effect size (Faul et al., 2009). In research studies, commonly used values for
power is 0.80 or 80% i.e. beta {β} equals 0.20 (Lenth, 2001). An increase in statistical
power is usually achieved by increasing sample size, as well as selecting stronger effect
sizes and significance levels (Jones et al., 2003). Generally, in sample size calculations, a
small sample size may potentially lead to inaccurate results not representative of the
study population (Jones et al., 2003).To determine the estimated sample size needed for
this study, a priori analyses were carried out using G*Power to estimate the power of the
data collected from the SEER database.
It is critically important to determine the optimal sample size necessary to provide
precise estimates and reliable answers to study hypotheses. That is, the likelihood of (a)
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the rejection of the null hypothesis that there is no association between the variables:
race/ethnicity, age at diagnosis, histologic subtype, insurance, other determinants and late
stage endometrial cancer diagnosis, (b) the rejection of the null hypothesis that there is no
association between the variables: race/ethnicity, age at diagnosis, histologic subtype,
tumor grade, insurance, stage at diagnosis, marital status and receipt of surgery in women
diagnosed with endometrial cancer in the United States, (c) the rejection of the null
hypothesis that there is no significant difference by racial/ethnicity in 5-year survival of
women diagnosed with endometrial cancer in the United States, or (d) the rejection of the
null hypothesis that there is no significant difference in 5-year survival by health
insurance status of women diagnosed with endometrial cancer in the United States.
Research is based on the widely used convention of 95% confidence interval or 5% level
of significance and 10% margin of error.
Power analysis for multilevel logistic regression was conducted to assess the
relationship among factors specific to this population-based cross-sectional study using
the G*power software. According to Long (1997), maximum likelihood estimations
including logistic regression analysis should not be done with less than 100 cases, citing
500 cases as adequate, with at least 10 cases per predictor. Peduzzi et al. (1996) stated
that 10 times the number of predictors (k), should be required for the proportion (p) of
successes.
Where p is the prevalence or proportion of event of interest for the study; and k is
the number of covariates i.e. the number of independent variables in the study
(race/ethnicity, tumor grade, histologic subtype, and insurance coverage).
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The proportion of women diagnosed with endometrial cancer in the United States was
27.8 per 100,000 women per year based on 2014–2018 cases (NCI SEER, 2020).
Therefore, the minimum number of cases to include is approximately:
N = 10 k / p
N = 10(4) / 0.0278 = 1,438
Instrumentation and Operationalization of Constructs
Operationalization of the Variables
Study variables included four primary independent variables (race/ethnicity,
histologic subtype, tumor grade, and insurance coverage), and three dependent variables
(endometrial cancer stage at diagnosis, receipt of surgery, and survival). The
demographic variables analyzed in this study included age, race/ethnicity, insurance, and
marital status. Clinical variables included in analysis were stage of disease, tumor
histology, tumor grade, and treatment. Table 1 below presents study variables.
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Table 1
Research Variables, Measures, and Coding

Variable

SEER*Stat
Variable Name

Operational
Definition

Measurement

Race/Ethnicity

Race and Origin recode

NHW =1
NHB = 2
NHAIAN = 3
NHAPI = 4
Hispanic = 5

Nominal

Age at diagnosis

Age recode with
single ages and 85+

18-45 years = 1
46-55 years = 2
56-65 years = 3
66-75 years = 4
>=76 years = 5

Ordinal

Tumor
Histology

Histologic type
ICD-O-3

Endometroid =1
Uterine carcinosarcoma = 2
Serous carcinoma = 3
Clear-cell carcinoma = 4
Other or unspecified = 5

Nominal

Tumor
Histology

Histologic type
ICD-O-3

Non-aggressive = 1
Aggressive = 2

Nominal

Tumor grade

Grade

Well differentiated = 1
Moderately differentiated = 2
Poorly differentiated =3
Undifferentiated/Anaplastic = 4
Unknown = 5

Tumor Grade
(dichotomized)

Grade

Low-grade = 1
High-grade = 2

Nominal

Nominal
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Table 2 Continued

Treatment

First course
of treatment

Surgery (Yes) = 1
Surgery (No) = 2

Nominal

Insurance

Insurance recode

Uninsured = 1
Insured = 2
Medicaid = 3

Nominal

Stage of disease
at diagnosis

Derived AJCC Stage
Group, 7th ed (2010+)

Localized = 1
Regional = 2
Distant = 3

Nominal

Stage at
diagnosis
(dichotomized)

Derived AJCC Stage
Group, 7th ed (2010+)

Non-advanced = 1
Advanced = 2

Nominal

Survival

Survival in months

MMMM = Survival time
in months

Continuous

Marital status

Marital status at
diagnosis

Single = 1
Married = 2
Separated/Divorced = 3
Widowed = 4

Nominal
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Data Analysis Plan
Data were abstracted from the SEER database based on the assumption that the
registry collects accurate, well-defined, and complete information on the key variables
needed to address the research questions in this study, including characteristics of the
study population; exposures of interest; patient outcomes; and potential confounding
factors. After abstracting all necessary data for analysis, data cleaning and screening
procedures were implemented to examine the quality of the data collected. Data cleaning
and analyses were carried out between March and May 2020. Statistical screening
methods involved using SPSS to carry out descriptive statistics to summarize and
organize the data. According to Greenland and Finkle (1995), a common challenge when
evaluating large datasets required for most multivariate analyses is the problem of
handling missing data, whether the missing values are a function of a random or a
systematic process. During the data screening process, it was important to check for the
issue of missing data so as to identify and minimize the impact of errors or bias on study
results. Dataset was also checked and corrected for errors. Descriptive analysis was done
for all the variables using the cleaned dataset. Descriptive statistics were then presented
as frequencies and percentages to describe the distribution of study variables including
sociodemographic factors, tumor, and treatment characteristics. IBM SPSS Statistics for
Windows, version 25 (IBM Corp., Armonk, N.Y., USA) was used to perform all
analyses. Table 2 summarizes the data analysis plan for each research question.
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Table 3
Research Questions, Variables, and Statistical Tests

Research Questions

Variables

Statistical Tests

Q1: What determinants are
associated with late-stage
diagnosis of endometrial
cancer (Stage III and IV) in
the United States as compared
to women with Stage I and II
endometrial cancer diagnosis?

Race/ethnicity; Age at diagnosis; Stage of
disease; Histologic subtype; Tumor grade;
Insurance; Marital status

Chi-square
analysis;
Multivariable
logistic regression

RQ2: What determinants are
associated with receipt of
surgery in women diagnosed
with endometrial cancer in the
United States?

Race/ethnicity; Age at diagnosis; Stage of
disease; Receipt of surgery; Histologic
subtype; Tumor grade; Insurance; Marital
status

Chi-square
analysis;
Multivariable
logistic regression

RQ3: Are there racial/ethnic
differences in 5-year survival
of women diagnosed with
endometrial cancer in the
United States?

Race/ethnicity; Age at diagnosis;
Histologic subtype; Tumor grade; Receipt
of surgery; Marital status; Survival
months; Advanced stage diagnosis;
Endometrial cancer-cause specific
mortality; endometrial cancer

Kaplan-Meier
survival curves;
Log-rank test;
Multilevel Cox
proportional
hazards regression
models

RQ4: Is there a significant
difference in
5-year survival by health
insurance status of women
diagnosed with endometrial
cancer in the United States?

Race/ethnicity; Age at diagnosis;
Histologic subtype; Tumor grade; Receipt
of surgery; Marital status; Insurance
status; Survival months; Advanced stage
diagnosis; Endometrial cancer-cause
specific mortality

Kaplan-Meier
survival curves;
Log-rank test; Cox
proportional
hazards regression
models
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Analysis Plan Addressing Research Questions and Hypotheses
RQ1: Are race/ethnicity, age at diagnosis, histologic subtype, tumor grade,
insurance, stage at diagnosis, and marital status associated with late-stage diagnosis of
endometrial cancer (Stage III and IV) in the United States as compared to women with
Stage I and II endometrial cancer diagnosis?
H01: The determinants: race/ethnicity, age at diagnosis, histologic subtype, tumor
grade, insurance, stage at diagnosis, and marital status are not associated with late-stage
endometrial cancer diagnosis (Stage III and IV) in the United States as compared to
women with Stage I and II endometrial cancer diagnosis.
Ha1: The determinants: race/ethnicity, age at diagnosis, histologic subtype, tumor
grade, insurance, stage at diagnosis, and marital status are associated with late-stage
endometrial cancer diagnosis (Stage III and IV) in the United States as compared to
women with Stage I and II endometrial cancer diagnosis.
To test this hypothesis, chi-square analysis was used to assess what determinants
(race/ethnicity, age at diagnosis, histologic subtype, tumor grade, insurance, and marital
status) were associated with late-stage diagnosis of endometrial cancer (Stage III and IV)
in the US versus early-stage (I and II). Multivariate logistic regression analysis were
performed to measure the association between study variables and late-stage endometrial
cancer diagnosis. Both unadjusted and adjusted odds ratios (OR) with their corresponding
95% confidence interval (CI) were calculated. All tests were evaluated at a 2-sided
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significance level of p<0.05. SPSS version 25 (IBM Corp., Armonk, N.Y., USA) was
used for all analyses.
RQ2: Are race/ethnicity, age at diagnosis, histologic, subtype, tumor grade,
insurance, stage at diagnosis, and marital status associated with receipt of surgery in
women diagnosed with endometrial cancer in the United States?
H02: The determinants: race/ethnicity, age at diagnosis, histologic subtype, tumor
grade, insurance, stage at diagnosis, and marital status are not associated with receipt of
surgery in women diagnosed with endometrial cancer in the United States.
Ha2: The determinants: race/ethnicity, age at diagnosis, histologic subtype, tumor
grade, insurance, stage at diagnosis, and marital status are associated with receipt of
surgery in women diagnosed with endometrial cancer in the United States.
To test this hypothesis, chi-square analysis was used to assess what determinants
(race/ethnicity, age at diagnosis, stage at diagnosis, histologic subtype, tumor grade,
insurance, and marital status) were associated with receipt of surgery as primary
treatment for endometrial cancer patients. Multivariate logistic regression analysis were
performed to measure the association between study variables and receipt of surgery.
Both unadjusted and adjusted odds ratios (OR) with their corresponding 95% confidence
interval (CI) were calculated. All tests were evaluated at a 2-sided significance level of
p<0.05. SPSS version 25 (IBM Corp., Armonk, N.Y., USA) was used for all analyses.
RQ3: Are there racial/ethnic differences in 5-year survival of women diagnosed
with endometrial cancer in the United States?
H03: There is no significant difference by racial/ethnicity in 5-year survival of

51
women diagnosed with endometrial cancer in the United States.
Ha3: There is a significant difference by racial/ethnicity in 5-year survival of
women diagnosed endometrial cancer in the United States.
Kaplan-Meier curves were constructed to assess differences in mortality over
time; racial/ethnic differences in survival were evaluated with the log-rank test.
Multilevel Cox proportional hazards regression models were applied to analyze the
racial/ethnic disparities in endometrial cancer-cause specific mortality while controlling
for potential confounders. All tests were evaluated at a 2-sided significance level of
p<0.05. SPSS version 25 (IBM Corp., Armonk, N.Y., USA) was used for all analyses.
RQ4: Is there a significant difference in 5-year survival by health insurance status
of women diagnosed with endometrial cancer in the United States?
H04: There is no significant difference in 5-year survival by health insurance
status of women diagnosed with endometrial cancer in the United States.
Ha4: There is a significant difference in 5-year survival by health insurance status
of women diagnosed with endometrial cancer in the United States.
Chi-square tests were employed to analyze the relationship between insurance and
all other covariates. Kaplan-Meier survival curves were used to calculate cumulative 5year survival, and cox proportional hazards regression models were used to estimate
hazard ratio (HR) and 95% conﬁdence intervals (CIs) for cause-speciﬁc survival within 5
years after diagnosis. All tests were evaluated at a 2-sided significance level of p<0.05.
SPSS version 25 (IBM Corp., Armonk, N.Y., USA) was used for all analyses.
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Treatment of Missing Data
The goal was to conduct statistical analyses using complete data only. However, if
necessary, multiple imputation method could be used to impute missing data and produce
estimates of the parameter(s) of interest. Sensitivity analysis was conducted to examine
whether missing data could have biased any of the study findings.
Threats to Validity
The primary goal of this research study was to generate valid results with minimal
error. It was therefore important to ensure the internal and external validity of this study.
The data used for this observational study were from the SEER database, a nationally
representative population-based dataset. Studies have shown that a large sample size is a
major advantage of using cancer registry datasets (Magee, Lee, Giuliano, & Munro,
2006; Park et al., 2012). Due to its large sample size, analytic results from this study were
more generalizable and minimized threats to external validity. In contrast, internal
validity is the “extent to which systematic error is minimized during the process of data
collection” (Shadish, Cook, & Campbell, 2002). Threats to validity based on
methods of data collection are quite common in secondary data analyses. SEER use
of data collection and quality standards by registry personnel allowed for an internal
consistency that minimized potential bias (Duggan et al., 2016). To avoid errors that
could influence study conclusions, any degree of random error was evaluated using
statistical methods. Additionally, statistical analysis was carried out to ensure data were
not missing at random as this could impact incidence and survival estimates of
endometrial cancer cases; it could also be a source of bias affecting internal validity. Any
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potential threat to statistical conclusion validity like low statistical power that could
prevent this retrospective study of cross-sectional data from detecting a true effect was
mitigated by using a large sample size, selecting reliable outcome measures and using
appropriate statistical tests for data analysis.
Ethical Procedures
The Surveillance, Epidemiology and End Results (SEER) program of the National
Cancer Institute gave permission to access its Research Data File after signing a Research
Data Agreement form with an option to download required files with the assigned
username and password.
Human Subjects Protection
The SEER program emphasizes the need to protect the identities of cancer
patients. Since study analysis was carried out using secondary data, there was no direct
access to human participants in this research study. SEER data was de-identified i.e. all
identifying information on individual patients have been removed from the data files
thereby eliminating any risks of disclosure of confidential or private information that
could constitute bias or conflict of interest by the researcher. This research study with
information on data usage for the primary purpose of analysis was submitted to the
Institutional Review Board (IRB) at Walden University for approval. IRB approval
number #02-20-20-0588627.
Ethical Concerns
U.S. Cancer registries including the SEER registry do not have uniform
procedures for identifying and contacting potential research participants so there is
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limited information on ethical concerns related to recruitment materials and processes
(Beskow, Sandler, & Weinberger, 2006). However, the implemented Health Insurance
Portability and Accountability Act (HIPAA) mandates cancer registries to engage in
ethical recruitment practices that maximize privacy protections such as educating patients
about the registry, involving physicians in patient recruitment, and initiating contact with
only patients who indicate an interest in participating after receiving an introductory letter
about the study. Using secondary data is based on the assumption that recruitment
activities in the SEER program take place within the context of well-established practices
for ethically responsible research with the primary aim of minimizing risk to participants.
SEER data quality improvement strategies also include cancer registry personnel
involved in the data collection process to sign statements that prevent the use of data and
safeguard patient confidentiality.
Treatment of Data
The data obtained from SEER were anonymous, and as specified in the Research
Data Agreement form, there were no attempts made to identify individuals, and research
results were presented such that they contained no patient identifiers. This researcher
maintained the utmost integrity and professionalism in handling data throughout the
research process. Data were stored as a password-protected file and securely saved on a
personal computer. To maintain patient confidentiality, the SEER data file and all
supporting documents will be permanently deleted from the computer on completion of
this doctoral study.
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Summary
In summary, this chapter presented a focused discussion on the research design
and methodology used in this quantitative retrospective cross-sectional study. Secondary
data obtained from the NCI SEER database was used to answer research questions aimed
at ascertaining the determinants of endometrial cancer survival disparities in the U.S.
Study results and findings were discussed in section 3.
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Section 3: Presentation of the Results and Findings
Introduction
This section highlights the results and findings generated from the analyses of the
research questions and hypotheses presented in this study. This is a quantitative
secondary analysis using SEER data to ascertain the determinants associated with
endometrial cancer survival disparities in the United States. The SEM is the conceptual
framework used to guide this study. The following research questions and hypotheses
were evaluated in this study:
RQ1: Are race/ethnicity, age at diagnosis, histologic subtype, tumor grade,
insurance, stage at diagnosis, and marital status associated with late-stage diagnosis of
endometrial cancer (Stage III and IV) in the United States as compared to women with
Stage I and II endometrial cancer diagnosis?
H01: The determinants: race/ethnicity, age at diagnosis, histologic subtype, tumor
grade, insurance, stage at diagnosis, and marital status are not associated with late-stage
endometrial cancer diagnosis (Stage III and IV) in the United States as compared to
women with Stage I and II endometrial cancer diagnosis.
Ha1: The determinants: race/ethnicity, age at diagnosis,
histologic subtype, tumor grade, insurance, stage at diagnosis, and marital status are
associated with late-stage endometrial cancer diagnosis (Stage III and IV) in the United
States as compared to women with Stage I and II endometrial cancer diagnosis.
RQ2: Are race/ethnicity, age at diagnosis, histologic, subtype, tumor grade,
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insurance, stage at diagnosis, and marital status associated with receipt of surgery in
women diagnosed with endometrial cancer in the United States?
H02: The determinants: race/ethnicity, age at diagnosis, histologic subtype, tumor
grade, insurance, stage at diagnosis, and marital status are not associated with receipt of
surgery in women diagnosed with endometrial cancer in the United States.
Ha2: The determinants: race/ethnicity, age at diagnosis, histologic subtype, tumor
grade, insurance, stage at diagnosis, and marital status are associated with receipt of
surgery in women diagnosed with endometrial cancer in the United States.
RQ3: Are there racial/ethnic differences in 5-year survival of women diagnosed
with endometrial cancer in the United States?
H03: There is no significant difference by racial/ethnicity in 5-year survival of
women diagnosed with endometrial cancer in the United States.
Ha3: There is a significant difference by racial/ethnicity in 5-year survival of
women diagnosed endometrial cancer in the United States.
RQ4: Is there a significant difference in 5-year survival by health insurance status
of women diagnosed with endometrial cancer in the United States?
H04: There is no significant difference in 5-year survival by health insurance
status of women diagnosed with endometrial cancer in the United States.
Ha4: There is a significant difference in 5-year survival by health insurance status
of women diagnosed with endometrial cancer in the United States.
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This section includes information on data collection, the descriptive and demographic
characteristics of the sample, and a summary of results from the series of statistical
analyses performed to test the research questions and hypotheses.
Data Collection of Secondary Data Set
Data were collected from the NCI’s SEER database, which includes data on
cancer incidence and survival from population-based cancer registries in the United
States. The first step to accessing SEER data is to sign the SEER Data-Use Agreement
form which emphasizes essential guidelines for using the data. I signed the SEER DataUse Agreement form and received approval in November 2019 (Appendix A) to access to
SEER 1975–2016 Research Database. I used the SEER*Stat software to download the
SEER 18: 1975-2016 Research Data File (November 2018 Submission) through an
internet connection i.e., SEER*Stat's client-server mode to specifically obtain data for
women diagnosed with endometrial cancer from 2007 through 2016. The variables
selected for data collection were race/ethnicity, age at diagnosis, tumor grade, stage of
disease, histology, treatment, insurance, survival time, and marital status. The initial
dataset consisted of 130,375 deidentified cases of endometrial cancer. The IBM SPSS
version 25 software application was used to carry out further analysis of study variables.
Characteristics of the study population
The endometrial cancer (corpus uteri and uterus, NOS) incidence and mortality
data were obtained from the NCI SEER database which includes women who were
diagnosed with primary invasive stages I, II, III or IV uterine corpus tumors between
2007 and 2016. However, women with in-situ cancers, uterine sarcomas, or a previous
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history of cancer were excluded from analysis (N = 130,375). The analysis was also
restricted to women ages 18 to 99 (N = 130,366). Patients were excluded if they were
missing data on or marital status (N = 7,629), race/ethnicity (N = 522), insurance (N =
2,557), treatment (N = 191), and stage at diagnosis (N = 3,150). Treatment information
includes patients who did or did not receive surgery (hysterectomy) as primary therapy.
The ﬁnal analytic cohort contained 115,997 patients.
There were several factors taken into consideration to ensure the
representativeness of the data sample to the target population with respect to the
determinants of interest in this study. Based on tumor histology, each cancer was
designated as one of the following types: endometrioid, uterine carcinosarcoma, serous
carcinoma, clear-cell carcinoma, and other/unspecified endometrial cancer. The variable
“stage at diagnosis” was classified as localized, regional, or distant; and further
dichotomized as non-advanced stage (localized), and advanced stage (regional or distant).
Tumor grade was classified as well differentiated, moderately differentiated, poorly
differentiated, undifferentiated, and unknown. To ascertain the factors associated with
advanced-stage disease, two groups were compared in this analysis; women diagnosed
with late-stage endometrial cancer (Stage III and IV) and women diagnosed with early
stage (Stage I and II) endometrial cancer. To explore survival disparities by
race/ethnicity, the variable was categorized as non-Hispanic White (NHW), non-Hispanic
Black (NHB), American Indian/Alaska Native (NHAIAN), Asian/Pacific Islander
(NHAPI), and Hispanic women. For this analysis, Hispanics includes all “persons of
specific Hispanic/Latino origins” (e.g., Mexican, Cuban, Puerto Rican (SEER, 2018).

60
The determinant, age at diagnosis, was categorized as follows: 18–45, 46–55, 56–65, 66–
75, 76 and over. To examine whether types of insurance are associated with survival
disparities for endometrial cancer patients, uninsured patients, insured patients (includes
private insurance and Medicare), and Medicaid-insured patients were compared. The
“marital status” variable was grouped into four main categories: single, married,
separated/divorced, and widowed. The “treatment” variable was categorized as patients
who received surgery (yes) or did not receive surgery (no) as primary treatment.
Chi-square test for univariate analysis was used to examine demographic and
socioeconomic characteristics of endometrial cancer patients. The study population
included 115,997 patients, the majority 80,275 (69.2%) being NHW women, 11,579
(10.0%) were NHB women, 733 (0.6%) were NHAIAN, 9,573 (8.3%) were NHAPI, and
13,837 (11.9%) were Hispanic. Patients over the age of 45 were more likely to be
diagnosed with endometrial cancer. Most diagnosed patients were aged 56–65 (35.2%),
followed by patients aged 66–75 (24.1%), then 46–55 (19.3%), with only about 7.9 % of
patients diagnosed in the 18–45 age group. Histological characteristics showed that
85,157 (73.4%) of endometrial cancer patients presented with endometroid tumors, with
less favorable subtypes such as uterine carcinosarcomas (11.5%), serous carcinomas
(6.8%), clear cell carcinomas (1.3%), and other/unspecified cases consisted of 6.9% of all
cases. Although 23.7% of patients reported unknown tumor grade, well differentiated
(31.9%), moderately differentiated (20.7%), poorly differentiated (16.3%), and
undifferentiated/anaplastic tumors (7.3%), made up endometrial cancer cases,
respectively. Additionally, of the total number of women included in the study, 98,985
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(85.3%) were insured, 13,383 (11.5%) had Medicaid, and 3,614 (3.1%) were uninsured.
Most patients were married 61,594 (53.1%), while 23,474 (20.2%) of patients were
single, 14,007 (12.1%) were separated/divorced, and 16,922 (14.6%) were widowed. The
presentation of early or nonadvanced stage disease occurred in 80,052 (69.0%) of women
compared to 35,945 (31.0%) of women who were diagnosed at advanced stage of disease.
Only 6,721 (5.8%) of endometrial cancer patients received surgical treatment as their first
course of cancer-directed therapy.
Results
Descriptive characteristics stratified by race/ethnicity are presented in Table 3.
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Table 4
Characteristics of Women Diagnosed with Endometrial Cancer, SEER 2007 – 2016 by
Race/Ethnicity

Characteristic

Age at Diagnosis
18-45
46-55
56-65
66-75
76+
Marital Status at Diagnosis
Single
Married
Separated/Divorced
Widowed
Insurance Type
Uninsured
Insured
Medicaid
Tumor Grade
Well Differentiated
Moderately Differentiated
Poorly Differentiated
Undifferentiated/Anaplastic
Unknown
Tumor Histology
Endometroid
Uterine Carcinosarcoma
Serous Carcinoma
Clear-cell Carcinoma
Other or Unspecified
Stage at Diagnosis
Non-Advanced
Advanced
Treatment (Surgery)
No
Yes

All patients
(N = 115,997)

Non-Hispanic
White
(N = 80,275)

Non-Hispanic
Black
(N = 11,579)

Non-Hispanic
American
Indian/Alaskan
Native
(N = 733)

Non-Hispanic
Asian/Pacific
Islander
(N = 9,573)

Hispanic
(N = 13,837)

Chisquare
p-value

9217 (7.9)
22383 (19.3)
40849 (35.2)
27961 (24.1)
15587 (13.4)

4435 (5.5)
14387 (17.9)
28656 (35.7)
20445 (25.5)
12352 (15.4)

902 (7.8)
1770 (15.3)
4404 (38.0)
3199 (27.6)
1304 (11.3)

131 (17.9)
192 (26.2)
236 (32.2)
129 (17.6)
45 (6.1)

1294 (13.5)
2650 (27.7)
3189 (33.3)
1671 (17.5)
769 (8.0)

2455 (17.7)
3384 (24.5)
4364 (31.5)
2517 (18.2)
1117 (8.1)

23474 (20.2)
61594 (53.1)
14007 (12.1)
16922 (14.6)

13916 (17.3)
44625 (55.6)
9529 (11.9)
12205 (15.2)

3786 (32.7)
3641 (31.4
2002 (17.3)
2150 (18.6)

231 (31.5)
345 (47.1)
85 (11.6)
72 (9.8)

1825 (19.1)
5992 (62.6)
693 (7.2)
1063 (11.1)

3716 (26.9)
6991 (50.5)
1698 (12.3)
1432 (10.3)

3629 (3.1)
98985 (85.3)
13383 (11.5)

1795 (2.2)
72511 (90.3)
5969 (7.4)

617 (5.3)
8842 (76.4)
2120 (18.3)

19 (2.6)
473 (64.5)
241 (32.9)

304 (3.2)
7755 (81.0)
1514 (15.8)

894 (6.5)
9404 (68.0)
3539 (25.6)

<0.001

37013 (31.9)
24064 (20.7)
18900 (16.3)
8511 (7.3)
27509 (23.7)

26619 (33.2)
17549 (21.9)
12055 (15.0)
5307 (6.6)
18745 (23.4)

2043 (17.6)
1870 (16.1)
2934 (25.3)
1535 (13.3)
3197 (27.6)

259 (35.3)
123 (16.8)
114 (15.6)
35 (4.8)
202 (27.6)

3292 (34.4)
1830 (19.1)
1636 (17.1)
738 (7.7)
2077 (21.7)

4800 (34.7)
2692 (19.5)
2161 (15.6)
896 (6.5)
3288 (23.8)

<0.001

85157 (73.4)
13348 (11.5)
7930 (6.8)
1563 (1.3)
7999 (6.9)

61428 (76.5)
8671 (10.8)
4646 (5.8)
980 (1.2)
4550 (5.7)

6111 (52.8)
2161 (18.7)
1691 (14.6)
252 (2.2)
1364 (11.8)

573 (78.2)
69 (9.4)
38 (5.2)
10 (1.4)
43 (5.9)

7031 (73.4)
999 (10.4)
666 (7.0)
135 (1.4)
742 (7.8)

10014 (72.4)
1448 (10.5)
889 (6.4)
186 (1.3)
1300 (9.4)

<0.001

80052 (69.0)
35945 (31.0)

57091 (71.1)
23184 (28.9)

6500 (56.1)
5079 (43.9)

515 (70.3)
218 (29.7)

6515 (68.1)
3058 (31.9)

9431 (68.2)
4406 (31.8)

<0.001

109276 (94.2)
6721 (5.8)

75881 (94.5)
4394 (5.5)

10590 (91.5)
989 (8.5)

688 (93.9)
45 (6.1)

9056 (94.6)
517 (5.4)

13061 (94.4)
776 (5.6)

<0.001

<0.001

<0.001
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According to chi-square results, there was a significant difference in age at
diagnosis of endometrial cancer patients across race/ethnicity groups (p < .001). The
youngest age group (18–45), NHAIAN (17.9%) and Hispanic (17.7%) women were more
likely to be diagnosed with endometrial cancer compared to other racial/ethnic groups
(NHW 5.5%; NHB 7.8%; NHAPI 13.5%). However, with increasing age, NHAPI
(27.7%), NHAIAN (26.2%) and Hispanic (24.5%) women were more likely to be
diagnosed with endometrial cancer in the age group 46–55 compared to NHW (17.9%)
and NHB (15.3%) women. For the age group 56–65, although prevalence of endometrial
cancer was high across all racial/ethnic groups (NHW 35.7%; NHAIAN 32.2%; NHAPI
33.3%; Hispanic 31.5%), NHB women (38.0%) still had a higher proportion of cases.
NHB (27.6%) and NHW (25.5%) patients were more likely to be diagnosed at age of 66–
75 compared to other racial/ethnic groups (NHAIAN 17.6%; NHAPI 17.5%; Hispanic
18.2%). NHW patients (15.4%) were more likely to be diagnosed over the age of 76
compared to other racial/ethnic groups (NHB 11.3%; NHAIAN 6.1%; NHAPI 8.0%;
Hispanic 8.1%). NHB women were more likely to be unmarried at the time of diagnosis
(32.7%) (p < .001). While NHW patients (55.6%) and NHAPI (62.6%) patients were
more likely to be married compared to patients from other racial/ethnic groups (NHB
31.4%; NHAIAN 47.1%; Hispanic 50.5%) NHW patients were more likely have health
insurance coverage (90.3%) and were less likely to be enrolled in Medicaid (7.4%), the
lowest rate across other racial/ethnic groups
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(p < .001). Medicaid enrollees were more likely to be NHAIAN patients (32.9%),
Hispanic (25.6%), NHB (18.3%), and NHAPI (15.8%). NHB patients (5.3%) and
Hispanics (6.5%) were more likely to be uninsured.
NHB women were twice (43.9%) as likely to be diagnosed with advanced stage
endometrial cancer compared with NHW (28.9%), NHAIAN (29.7%), NHAPI (31.9%),
and Hispanics (31.8%; p < .001). In comparing tumor pathological characteristics, tumor
histology and grade differed significantly by race/ethnicity (p < .001). NHB were more
likely to have aggressive endometrial cancer based on tumor histology of all nonendometrioid carcinomas. In particular, uterine carcinosarcoma (NHW 10.8%; NHB
18.7%; NHAIAN 9.4%; NHAPI 10.4%; Hispanic 10.5%) and clear-cell carcinoma were
two times more likely to occur in NHB patients (NHW 1.2%; NHB 2.2%; NHAIAN
1.4%; NHAPI 1.4%; Hispanic 1.3%), while cases of serous carcinoma (NHW 5.8%;
NHB 14.6%; NHAIAN 5.2%; NHAPI 7.0%; Hispanic 6.4%) were three times more
likely to occur in NHB patients compared to other racial/ethnic groups. In contrast, NHB
women were less likely to be diagnosed with endometroid uterine corpus tumors. In
addition, NHB were more likely to be diagnosed with higher grade disease. Compared to
other racial/ethnic groups (NHW 5.5%; NHAIAN 6.1%; NHAPI 5.4%; Hispanic 5.6%),
NHB patients (8.5%) were more likely to receive surgery as primary treatment of
endometrial cancer (p < .001).
Factors Associated with Advanced Stage Diagnosis
In multivariable analysis (stepwise logistic regression), after adjusting for age,
insurance, tumor histology and grade, NHB women were at an increased risk for
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advanced stage disease. The risk for NHB women to present with advanced stage disease
was significantly higher than for NHW women (odds ratio [OR] = 1.16; 95% confidence
interval [CI] = 1.11, 1.22) (Table 4). NHAPI also reported an increased risk of late-stage
disease compared to NHW women (OR = 1.16; 95% CI = 1.10, 1.22). However, this
association was not significant in NHAIAN and Hispanic patients. Other factors
associated with increased risk for advanced stage disease were increasing age, poor tumor
grade, and aggressive tumor histology. Age was associated with advanced stage disease
for each subgroup [46-55 years (OR = 1.12; 95% CI = 1.05, 1.20); 56-65 years (OR =
1.08; 95% CI = 1.02, 1.15); 66-75 years (OR = 1.13; 95% CI = 1.06, 1.21); 76+ (OR =
1.29; 95% CI = 1.20, 1.39)]. Tumor histology was stratified as “aggressive” and
“nonaggressive” histology; study analyses showed a strong association between tumor
histology and stage at diagnosis (OR = 2.22; 95% CI = 2.14, 2.30). Similarly, there was
an increasingly strong association with tumor grade and advanced stage disease at these
subgroups [moderately-differentiated tumors (OR = 2.74; 95% CI = 2.62, 2.86); poorlydifferentiated tumors (OR = 5.86; 95% CI = 5.59, 6.14); undifferentiated tumors (OR =
6.01; 95% CI = 5.63, 6.41) when compared to well-differentiated tumors. In addition,
having insurance was associated with a decreased risk for advanced stage disease (OR =
0.74; 95% CI = 0.68, 0.80). However, the association was not significant in the analysis
of patients with Medicaid.
Receipt of Surgery Treatment
Depending on the extent of the disease in patients, the main treatment for
endometrial cancer is hysterectomy, i.e., the surgical removal of a woman's uterus, and
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cervix (ACS, 2018). Surgical treatment is most successful at early stage of disease. Only
5.8% of all endometrial cancer patients received surgery as their primary treatment
(Table 3). In the univariate analysis, race/ethnicity was not associated with receipt of
surgery. After controlling for stage at diagnosis in the multivariate analysis, race/ethnicity
and marital status were not independently associated with receipt of surgery. Results
from analysis also showed that insured patients (OR = 0.84; 95% CI = 0.73, 0.97) and
patients with Medicaid (OR = 0.81; 95% CI = 0.69, 0.95) were less likely to receive
surgery treatment (Table 4). With increase in age, patients were less likely to receive
surgery as primary treatment [56–65 years (OR = 0.76; 95% CI = 0.67, 0.85); 66–75
years (OR = 0.77; 95% CI = 0.68, 0.86); 76+ (OR = 0.58; 95% CI = 0.51, 0.67).
However, for the age group 46–55 years, the results were not significant (OR = 1.01; 95%
CI = 0.94, 1.09). In the multivariate analysis, women of increased age were less likely to
receive a hysterectomy. Although surgery as a first course of cancer-directed therapy is
most frequently recommended for women with localized uterine corpus tumors, the
analysis of predictors of receipt of surgery showed similar results of a strong association
for patients who presented with aggressive histology (OR = 1.80; 95% CI = 1.68, 1.92,
and advanced stage disease (OR = 3.20; 95% CI = 3.02, 3.40). In addition, tumor grade
was associated with an increasingly strong association with receipt of surgery. Patients
with [moderately-differentiated tumors (OR = 1.32; 95% CI = 1.20, 1.45); poorlydifferentiated tumors (OR = 2.10; 95% CI = 1.92, 2.31); undifferentiated tumors (OR =
2.02; 95% CI = 1.80, 2.27)] were more likely to receive a hysterectomy.
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Table 5
Variables Associated with Advanced-Stage Disease and Receipt of Surgery
Characteristic

Race/Ethnicity
NH White
NH Black
NHAIAN
NHAPI
Hispanic
Age at Diagnosis
18-45
46-55
56-65
66-75
76+
Marital Status at Diagnosis
Single
Married
Separated/Divorced
Widowed
Insurance Type
Uninsured
Insured
Medicaid
Stage at Diagnosis
Non-advanced
Advanced
Tumor Grade
Well Differentiated
Moderately Differentiated
Poorly Differentiated
Undifferentiated/Anaplastic
Unknown
Tumor Histology
Non-aggressive
Aggressive

Advanced Stage Diagnosis
ORa (95% CI)

Receipt of Surgery
ORa (95% CI)

REF
1.16 (1.11 – 1.22)
1.09 (0.92 – 1. 31)
1.16 (1.10 – 1.22)
1.09 (1.04 – 1.14)

REF
1.04 (0.96 – 1.13)
1.09 (0.79 – 1.52)
0.82 (0.74 – 0.92)
0.89 (0.81 – 0.97)

REF
1.12 (1.05 – 1.20)
1.08 (1.02– 1.15)
1.13 (1.06 – 1.21)
1.29 (1.20 – 1.39)

REF
0.90 (0.79 – 1.01)
0.76 (0.67 – 0.85)
0.77 (0.68 – 0.86)
0.58 (0.51 – 0.67)

REF
0.75 (0.72 – 0.78)
0.84 (0.80 – 0.88)
0.90 (0.86 – 0.95)

REF
1.01 (0.94 – 1.09)
0.92 (0.83 – 1.01)
1.01 (0.92 – 1.12)

REF
0.74 (0.68 – 0.80)
0.94 (0.86 – 1.03)

REF
0.84 (0.73 – 0.98)
0.81 (0.69 – 0.95)

-

REF
3.21 (3.02 – 3.40)

REF
2.74 (2.62 – 2.86)
5.86 (5.59 – 6.14)
6.01 (5.63 – 6.41)

REF
1.32 (1.20 – 1.45)
2.10 (1.92 – 2.31)
2.02 (1.80 – 2.27)

2.65 (2.54 – 2.77)

1.45 (1.32 – 1.59)

REF
2.22 (2.14 – 2.30)

REF
1.80 (1.68 – 1.92)

Note.
NH = Non-Hispanic; AIAN = American Indian/Alaskan Native; API = Asian/Pacific Islander.
OR = odds ratio; CI = confidence interval;
aORs derived from the logistic regression model; REF=reference level.
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Survival
Factors Associated with Endometrial Cancer-Specific Mortality
Cox proportional hazards model showing variables associated with risk for death
are shown in table 5. Based on analysis of the 5-year study period, 14,053 (20.8%)
women died of endometrial cancer. The number of deaths was disproportionately higher
in NHB women (N = 2,748; 35.2%; p < .001) compared to NHW women (N = 8,570;
19.3%; p < .001). Among other minority women, NHB women had the highest overall
mortality, followed by NHAIAN women (N = 443; 19.6%; p < .001), then Hispanic
women (N = 9,064; 18.2%; p < .001), and then NHAPI (N = 5,760; 17.4%; p < .001).
Using Cox proportional hazard multivariable analysis, after adjusting for age at
diagnosis, marital status, tumor grade, histologic subtype, stage at diagnosis, type of
treatment and insurance status, the hazard of disease-specific mortality was increased for
NHB women compared to NHW women (Hazard ratio [HR] = 1.33; 95% CI = 1.27, 1.39;
p < .05) (Table 5). There is no evidence of a difference between all other racial/ethnic
groups and NHW women. Women aged 65 years and older had a higher risk of death due
to endometrial cancer compared with women diagnosed below the age of 65 years
(HR = 1.56; 95% CI = 1.50, 1.62; p < .05). Being married was a protective factor against
endometrial cancer death; patients who were married were 18% less likely to die from
endometrial cancer compared with unmarried patients (HR = 0.82; 95% CI = 0.79, 0.86;
p < .05). The risk of death from endometrial cancer significantly increased in patients
diagnosed with aggressive histologic subtype (HR = 1.58; 95% CI = 1.52, 1.65; p < .05);
risk was 3 times higher in patients diagnosed with high-grade tumors (HR = 3.20; 95% CI
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= 3.05, 3.35; p < .05), and 5 times higher in patients diagnosed with advanced stage
disease (HR = 5.88; 95% CI = 5.65, 6.13; p < .05). Having insurance, whether private
insurance or Medicare showed a protective effect against endometrial cancer causespecific mortality as risk of death decreased by 32% (HR = 0.68; 95% CI = 0.63, 0.74;
p < .05) compared to patients with no insurance. The hazard for patients with Medicaid
also showed a decrease of 16% when compared to patients with no insurance (HR = 0.84;
95% CI = 0.77, 0.92; p < .05). Receipt of surgery treatment was independently associated
with an increased risk (HR = 1.26; 95% CI = 1.20, 1.33; p < .05) for endometrial cancer
death.
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Table 6
Adjusted Hazard Ratios for Endometrial Cancer-Cause Specific Mortality
Characteristic

Endometrial Cancer-Cause Specific
Mortality
(N = 67,478)
HR (95% CI)

Race/Ethnicity
NH White
NH Black
NHAIAN
NHAPI
Hispanic
Age at Diagnosis
< 65
≥ 65
Marital Status at Diagnosis
Single
Married
Separated/Divorced
Widowed
Insurance Type
Uninsured
Insured
Medicaid
Stage at Diagnosis
Non-advanced
Advanced
Tumor Grade
Low-grade
High-grade
Unknown
Tumor Histology
Non-aggressive
Aggressive
Unknown
Treatment
Non-aggressive
Aggressive
Note.
HR = hazard ratio; CI = confidence interval.
a
HRs derived from the Cox proportional hazards model.
Ref., reference group. * p < .05

REF
1.33 (1.27 – 1.39)
1.08 (0.88 – 1. 33)
0.96 (0.90 – 1.02)
1.01 (0.96 – 1.07)
REF
1.56 (1.50 – 1.62)
REF
0.82 (0.79 – 0.86)
0.98 (0.93 – 1.04)
1.23 (1.17 – 1.30)
REF
0.68 (0.63 – 0.74)
0.84 (0.77 – 0.92)
REF
5.88 (5.65 – 6.13)
REF
3.20 (3.05 – 3.35)
2.60 (2.47 – 2.73)
REF
1.58 (1.52 – 1.65)
3.44 (3.28 – 3.61)
REF
1.26 (1.20 – 1.33)
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Disease-Specific Survival by Race/ethnicity and Disease Stage
Five-year survival rates were much lower in NHB women than other racial/ethnic
groups diagnosed with endometrial cancer. The overall survival time was shorter among
NHB women, compared to other racial/ethnic groups (Figure 2). The median survival
time among NHB women was 49.0 months (95% CI = 46.8, 51.2); compared to NHW
women who had a longer survival time. This disparity in survival remained the same with
multivariable analysis (HR = 1.33; p < .05) (Table 5).
Additionally, of all the determinants included in the multivariable analysis, stage at
diagnosis had a more significant impact on survival of women diagnosed with
endometrial cancer. Sub-analysis of the interaction between race/ethnicity and stage at
diagnosis shows racial/ethnic differences in survival time within each disease stage. The
survival rate at five years from diagnosis showed that NHB women experienced worse
survival outcomes for all stages combined. For localized disease, all racial/ethnic groups
had similarly longer survival times (Figure 3); However, NHB women had a higher risk
of death when presenting with advanced stage disease. For regional disease, the median
survival time for NHB women was 34.0 months (95% CI = 31.4, 36.6) compared to 56.0
months (95% CI = 54.7, 57.3; p < .05) among NHW women; while distant-stage disease
showed a median survival time of 9.0 months for NHB women (95% CI = 8.2, 9.7)
versus 12.0 months (95% CI = 11.3, 12.7; p < .05) for NHW women. However,
differences in survival time within each disease stage was less apparent among all other
racial/ethnic groups when compared to NHW women.
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Figure 2
Cumulative 5-year Survival Curves for Women Diagnosed with Endometrial
Cancer, by Race/Ethnicity

Note. Kaplan–Meier log-rank tests, * p < .05
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Figure 3
Cumulative 5-year Survival Curves for Women Diagnosed with Endometrial Cancer, by
Race/Ethnicity and Stage of Diagnosis

Note. Kaplan–Meier log-rank tests, * p < .05
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Disease-Specific Survival by Insurance
Kaplan–Meier survival curves for insurance status of endometrial cancer patients
are depicted in Figure 4. Of the women who died of endometrial cancer, 27.8% of
patients had no insurance, 24.6% were enrolled in Medicaid, and 19.9% were privately
insured. There was a significant difference in the estimated 5-year survival of women
diagnosed with endometrial cancer (p < .05). In examining the association between health
insurance status and survival, estimated 5-year cause-speciﬁc survival was higher for
privately insured patients. Survival analysis for insurance status, stratified by stage at
diagnosis, showed that uninsured patients and Medicaid enrolled patients with advanced
stage disease had a significantly higher risk of death within 5 years of diagnosis (23.0
months; 95% CI = 18.8, 27.2) and (26.0 months; 95% CI = 24.0, 27.9) respectively, while
privately insured patients had a longer survival time of 34.0 months (95% CI = 32.9,
35.1).

75
Figure 4
Cumulative 5-year Survival Curves for Women Diagnosed with Endometrial Cancer, by
Insurance

Note. Kaplan–Meier log-rank tests, * p < .05
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Figure 5
Cumulative 5-year Survival Curves for Women Diagnosed with Endometrial Cancer, by
Insurance and Stage of Diagnosis

Note. Kaplan–Meier log-rank tests, * p < .05
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This chapter presented results of descriptive statistics and hypotheses testing for
the four research questions posed in this study. Specifically, to evaluate the independent
effect of variables: race/ethnicity, age at diagnosis, marital status, stage at diagnosis,
histologic subtype, tumor grade, treatment type, and insurance on endometrial cancer
survival. Logistic regression analysis were used to test the null hypothesis against the
alternative hypothesis (H1 or Ha) for the first two research questions. The findings of
research question one indicated that the determinants, race/ethnicity, age at diagnosis,
tumor histology and grade significantly increased the risk of being diagnosed with latestage endometrial cancer (p < .001). Therefore, the null hypothesis was rejected.
However, insurance and marital status had no significant effect on late-stage diagnosis of
endometrial cancer, so the null hypothesis was not rejected. The findings of the second
research question showed that, tumor histology and grade, as well as stage at diagnosis
were the only determinants that independently had an impact on receipt of surgery among
women diagnosed with endometrial cancer (p < .001). Hence, the null hypothesis was
rejected. However, the null hypothesis was not rejected for the independent variables
race/ethnicity, age at diagnosis, insurance, and marital status as the results were not
significant.
For research question three, hazard ratios adjusted for age at diagnosis, marital
status, tumor grade, histologic subtype, stage at diagnosis, type of treatment and
insurance status, showed that disease-specific mortality increased significantly when
stratified by race/ethnicity (p < .05). Hence, the null hypothesis of no difference
regarding survival times and racial/ethnic groups was rejected. Similarly, for question
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four, there was a significant difference in the estimated 5-year survival of women
diagnosed with endometrial cancer stratified by insurance status (p < .05). Hence, the null
hypothesis that there is no difference in survival times between uninsured and insured
patients with endometrial cancer was rejected.
Summary
The results of this study established that multiple determinants were significantly
and consistently associated with late-stage endometrial cancer. The variables
race/ethnicity, older age, poor tumor grade, and aggressive tumor histology were
independent predictors of being diagnosed with late stage disease. NHB women were
twice more likely to be diagnosed with advanced stage disease compare to NHW women.
After adjusting for potential confounders in the multivariable analysis, health insurance
status did not independently affect advanced-stage disease. NHB women were twice
more likely to be diagnosed with advanced stage disease compare to NHW women.
Increasing age affected the likelihood of receiving surgery as primary treatment. Also,
patients who presented with aggressive histology, high grade tumors and advanced-stage
disease were more likely to receive surgical treatment. Race/ethnicity was not
independently associated with receipt of surgery after controlling for stage at diagnosis.
Therefore, the influence of individual- and contextual-level factors contributed to
racial/ethnic disparities in treatment for endometrial cancer.
Additionally, increasing age, race/ethnicity, aggressive histology, high grade
tumors and advanced-stage disease were associated with an increased risk of endometrial
cancer mortality; while having insurance was associated with a decreased risk for death.
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NHB women had a disproportionately worse disease- specific survival even after
adjusting for age, tumor histology and grade. There was a significant association between
health insurance status and survival, estimated 5-year cause-speciﬁc survival was higher
for privately insured patients. Survival analysis, stratified by stage of diagnosis, insured
and Medicaid insured cancer patients with advanced stage disease had poorer survival
outcomes compared to patients with insurance. A further review of study findings will be
discussed in Chapter 4, including the study’s application to professional practice and its
implications for social change.
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Section 4: Application to Professional Practice and Implications for Social Change
Introduction
The purpose of this study was to ascertain the determinants of endometrial cancer
survival disparities in the United States. Specifically, my goal was to evaluate the
independent effect of variables: race/ethnicity, age at diagnosis, marital status, stage at
diagnosis, histologic subtype, tumor grade, treatment type, and insurance on endometrial
cancer survival. The retrospective, cross-sectional study was carried out using
epidemiologic data from NCI SEER Database which contained the most current data
available on incidence and survival of endometrial cancer cases. The study sample
included 115,997 women diagnosed with endometrial cancer from 2007 to 2016. The key
findings suggest that causes of differences in endometrial cancer survival are
multifactorial; race/ethnicity, increasing age, poor tumor grade, and aggressive tumor
histology similarly influence the risk for presenting with advanced-stage endometrial
cancer. Non-Hispanic Black women had a higher risk of being diagnosed with advanced
stage endometrial cancer, and experienced worse disease-specific survival after
controlling for factors such age at diagnosis, histologic subtype, tumor grade, and
insurance. There were racial/ethnic disparities in survival rates; the 5-year overall
survival for non-Hispanic White women with endometrial cancer was 81%, compared
with 65% for non-Hispanic Black women. The interaction between race/ethnicity and
stage of disease also showed that non-Hispanic Black women had a higher risk of death
with advanced stage disease. Race/ethnicity was not an independent predictor of receipt
of surgery after controlling for stage of diagnosis in the multivariate analysis. With
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increased age, patients were less likely to receive surgery as primary treatment. However,
aggressive histology, high grade tumors and advanced-stage disease were associated with
receipt of surgery treatment in the multivariable analysis. There was a significant
association between health insurance status and survival; estimated 5-year cause-speciﬁc
survival was higher for privately insured patients. Survival analysis, stratified by stage of
diagnosis, showed that among patients with advanced disease, those with insurance had
better survival outcomes compared to patients with no insurance.
Interpretation of the Findings
Several studies have examined the racial/ethnic and socioeconomic factors
associated with disparities in endometrial cancer survival across different population
groups throughout the United States. It is well-documented that non-Hispanic Black
women have disproportionally worse survival due to several potential factors that
influence disease-specific mortality such as demographic and socioeconomic factors,
tumor characteristics, and treatment factors (Cote, et al., 2015; Long et al., 2013; RauhHain et al., 2015). However, it remains unclear why racial differences in survival persist
after accounting for these factors. Chatterjee et al. (2016) found that African American
women are more likely than White women to be diagnosed with advanced-stage disease,
high-grade tumors (Grade III or Grade IV), and were more likely to suffer poorer
prognosis. Additionally, Tarney et al. (2018) found that Black women with endometrial
cancer suffer significantly worse survival outcomes regardless of age, stage and grade of
disease. Findings from this study confirm these assumptions as increased age, African
American ethnicity, aggressive histologic subtype, high-grade tumors and advanced-
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stage disease were independently associated with increased risk for endometrial cancer
death, and poorer survival outcomes. African American women had a higher risk of being
diagnosed with aggressive histology, poor tumor grade, and advanced-stage disease.
Increasing age was independently associated with being diagnosed with late stage disease
across all racial/ethnic groups. The 5-year disease-specific survival was significantly
higher at 81% for non-Hispanic White women, compared to 65% for non-Hispanic Black
women; this racial/ethnic differences in survival was also evident within regional and
distant disease stage.
Studies have demonstrated that older women are more likely to be diagnosed with
high-grade uterine cancer tumors, poor histology, and advanced disease; thus, may
require surgery and/or adjuvant therapy (Ahmed et al., 2008; Duska et al.,2016; Wright et
al., 2011). Rauh-Hain et al. (2015) found that Black women with endometrial cancer are
less often to receive surgical treatment at every stage and grade of disease and have
poorer survival outcomes. While increasing age was not associated with receipt of
surgery, study findings confirm that endometrial cancer patients with aggressive
histology, poor tumor grade, and advanced-stage disease were more likely to undergo
surgery. There was no racial/ethnic differences observed with receipt of surgery among
women diagnosed with endometrial cancer.
The SEM was used as conceptual framework to explore the determinants of
endometrial cancer survival disparities in the United States. This model takes into
consideration the complexity of the multilevel interactions between individual,
interpersonal, community, organization, and societal factors. Currently, there is no known
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standard or routine screening test for endometrial cancer; hence the challenge to develop
and implement evidenced-based policies that promote early detection and timely
diagnosis. For this to happen, it requires a better understanding of perceived risk factors
that influence health outcomes at these different levels. This includes the range of
individual- and contextual-level factors such as the sociodemographic and tumor
characteristics that can influence survival outcomes. At the community level, insurance
plays a major role in predicting survival outcomes. The lack of adequate insurance
coverage and other supplemental health programs could limit the number of women who
seek medical care that could lead to early detection and timely diagnosis. Previous
studies, albeit few, have examined the effects of insurance status on cancer outcomes
including endometrial cancer. Findings have shown that uninsured and Medicaid insured
patients have poorer survival outcomes compared to privately insured patients (Fedewa et
al, 2011; Niu et al, 2013; Sohn, 2017). This is also consistent with study findings, except
for patients on Medicaid, insured patients were less likely to be diagnosed with advanced
stage endometrial cancer and reported signiﬁcantly lower risks of death than uninsured
and Medicaid insured patients.
Individual-level factors such as age, race/ethnicity, and marital status are also
important demographic characteristics that can influence survival outcomes. There is a
well-established association between marital status and survival in cancer patients;
married patients compared to unmarried patients have decreased mortality in several
malignances such as such as prostate, breast, cervical and colon cancers irrespective of
age, tumor grade, and disease stage (Hanske et al., 2016; Hinyard et al., 2017; Liu et al.,
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2019; Tyson et al., 2013; Wang et al., 2011). Lowery et al. (2015) examined the effect of
marriage on survival outcomes for women diagnosed with uterine cancer, and found that
compared to widows, married women experienced better uterine cancer survival
outcomes. This study has examined the effect of marital status as a prognostic factor for
survival of women diagnosed with endometrial cancer. The findings clearly indicate that
being married is associated with a decreased risk of endometrial cancer mortality.
Limitations of the Study
The study was conducted using data obtained from SEER database, a national
level cancer registry, which provides valid and reliable information related to endometrial
cancer incidence and survival data, as well as individual-level data related to cancer
diagnoses, histopathology and treatment characteristics across various demographic
groups (SEER, 2018). The SEER program provides access to population-based data that
is unique with regard to representativeness and generalizability to the U.S. population
(Duggan et al., 2016). A major strength of this study is the large sample size and the
representativeness of the study sample i.e., endometrial cancer patients diagnosed during
the study period allowed for more reliable and generalizable results. In addition, using an
appropriate sample size was critical to ensuring validity in this quantitative study. If the
sample size is too small, it will not yield valid results in the multivariable analyses (Jones
et al., 2003). Hence, a large sample size is necessary to estimate significant endpoints for
this study including cause-specific survival.
One major limitation of this study is that adequate data related to SES, risky
behavior, comorbidities, and other relevant health information are not available in the
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SEER database. Although not included in study analysis, these variables including
education, income, treatment regimen, smoking history, diabetes, and obesity have been
known to affect endometrial cancer survival. It is possible that exempting these variables
could have mitigated potentially confounding effects in this study. In addition, although
cancer-specific mortality and survival outcomes for Black women diagnosed with
endometrial cancer have improved over time, results from this study showed that the 5year overall survival for Black women was 65%, compared to 81% for non-Hispanic
White women, after controlling for confounding effects. This suggests that disparity in
survival may be attributed to not just socioeconomic and histopathologic differences, but
other unidentified factors not accounted for in this analysis.
Another limitation of this study is based on the underlying assumption that
information obtained from the SEER database on cause-speciﬁc survival is correctly
defined i.e., cause of death information obtained from death certificates was accurately
documented during data abstraction. That is, any misclassification of cause of death is a
major threat to the validity of study results for cause-specific survival. Finally, since this
is a retrospective, cross-sectional study, results were based on the analysis of multiple
variables captured at a specific point in time i.e., 2007 to 2016. Therefore, causality
cannot be inferred from this analysis. Nevertheless, study limitations are less probable to
influence the main conclusions of this study.
Recommendations
Research findings suggest that the determinants assessed in this study increased
the likelihood of presenting with late-stage disease and may also account for increased
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mortality from endometrial malignancy. However, they do not explain the differences in
prognosis and survival observed between African American women and Caucasian
women diagnosed with endometrial cancer. African American women were more likely
to present with advanced stage disease, more aggressive histologic subtypes, and poorer
tumor grade. There was also a significant decrease in survival among uninsured patients
compared to privately insured patients. This might suggest that disparities in survival
may be as a result of other influences such as comorbid conditions, socioeconomic status,
access to appropriate and timely treatment. Hence, the findings of this study support the
need for further research into the biologic mechanisms underlying differences in
histopathology, as well as socioeconomic and treatment factors associated with
disparities in endometrial cancer survival.
The survival disparity observed in African American women diagnosed with
endometrial cancer is multifactorial, and its complexity highlights the need for continued
research. Future studies should synthesize available evidence in literature to identify
important research questions and facilitate designing targeted interventions that can have
a real impact in reducing endometrial cancer disparities in the United States.
Methodology recommendations for future researchers include having robust study
methods and design to ensure validity of study results. It is important to ensure high
quality method and measurements techniques targeted to measure exactly the outcome of
interest. Some of the limitations of this study include data source, i.e. utilizing the SEER
database was based on the assumption that data collected were complete and accurate.
Researchers using information from large databases must assess the completeness and
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accuracy of information contained in the database. This may include data source,
geographic location of participant enrollment, techniques used in recruitment of
participants, exclusion and exclusion criteria used to determine eligibility of study
population, how patient demographics were defined and measured, and how outcome of
interest was defined and measured. Comprehensive data should also be obtained for
disease characteristics such as age at diagnosis, race/ethnicity, socioeconomic status, year
of diagnosis, cancer stage at diagnosis, tumor grade and histology, comorbidities, and
disease risk factors. In addition, the importance of developing specific research questions,
selecting a rigorous study design, and expertise in analytic methods should not be
underestimated.
Implications for Professional Practice and Social Change
The burden of endometrial cancer is significant. As the most commonly
diagnosed gynecologic malignancy in the United States, it has become imperative to
reverse the trend of increasing rates of endometrial cancer incidence and mortality.
Future implications for professional practice include identifying ways to improve early
detection of endometrial cancer, as well as advance professional practice and implement
policies at the state and national levels that promote better survival outcomes. Over time,
the Affordable Care Act (ACA) has expanded health insurance coverage for more women
to have access to equitable, timely and quality health care (Holland et al., 2016). Lowincome women who do not have insurance now benefit from the ACA’s Medicaid
expansion plan. Although uninsured rates in the United States have reduced substantially,
racial and ethnic disparities in the receipt of adequate healthcare still exist. Early
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diagnosis of disease improves overall prognosis so the significance of primary healthcare
services for women cannot be understated. Access to care, especially primary health care
practitioners can alleviate the burden of disease by earlier referrals to oncologists for
proper diagnosis and treatment.
As previously discussed, the positive social change implications of this research
study is primarily to improve survival outcomes for all women diagnosed with
endometrial cancer in the United States. This includes identifying factors associated with
increased mortality, and a better understanding of how those factors contribute to racial
and ethnic disparities in endometrial cancer. Therefore, potential policy recommendations
should focus largely on improving survival outcomes of subpopulations
disproportionately affected by the impact of individual and contextual-level factors
assessed in this study.
This includes:
1. Specific policy interventions targeted toward African American women who are
at increased risk for advanced stage diagnosis, higher disease mortality, and are
less likely to receive surgery treatment.
2. Advancing polices that ensure health insurance coverage includes potential
treatments for subpopulations at risk.
3. Improving access to care by increasing the capacity and number of healthcare
providers in underserved communities.
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4. Promoting the use of standardized protocols and procedures by healthcare
providers for the treatment of endometrial cancer so as to reduce racial/ethnic
disparities.
5. Increasing awareness of racial and ethnic disparities among healthcare providers
and the general public.
Conclusion
Endometrial cancer continues to be a major public health problem in the United
States as incidence and mortality continue to rise. There is also a widening survival
disparity observed among racial/ethnic groups, hence the need to examine multiple
determinants associated with decreased survival among women with endometrial cancer.
This study provided further evidence showing that disparities in survival cannot be fully
explained by factors assessed in this study, elucidating the need for more research to
explore other multilevel factors that may potentially contribute to disparities in
endometrial cancer outcomes. The key to improving survival rates for women diagnosed
with endometrial cancer is a better understanding of the complex interplay of multiple
factors that have been suggested to contribute to inequalities in endometrial cancer
outcomes. Population-based interventions should focus on increasing awareness of the
significant benefits of early detection and implementing policies that ensure accessibility
to quality health care services and treatment for all women.
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